A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020   
 
 
 
A Window of Opportunity  Trial  of Cetuximab  in 
Patients with Head and Neck Squamous Cell 
Carcinoma (HNSCC)  
NIDCR  Protocol  Numbers:  17-033 -E; 17-034 -E 
NIDCR Grant Number: P50 DE026787  
Principal Investigators:  Justine  Yang  Bruce,  MD 
Randall J. Kimple, MD, PhD  
NIDCR  Program Official:  Chiayeng  Wang,  PhD 
NIDCR Medical Monitor: Kevin McBryde, MD 
IND/IDE Sponsor: Not applicable  
 
 
 
  
 
  
 
 
[STUDY_ID_REMOVED] 
 
 
 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
2 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
  
STATEMENT OF COMPLIANCE  
The study will be conducted in accordance with the International Conference on 
Harmonisation guidelines for Good Clinical Practice (ICH E6), the Code of Federal Regulations  on the Protection  of Human  Subjects  (45 CFR Part 46), and the NIDCR 
Clinical Terms of Award. All personnel involved in the conduct of this study have completed human subjects protection training.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
3 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 SIGNATURE  PAGE  
The signatures  below  constitute  the approval  of this protocol  and the attachments,  and 
provide the necessary assurances that this trial will be conducted according to all 
stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal regulations and ICH guidelines.  
 
Principal  Investigators  or Clinical Site Investigators:  Justine  Yang  Bruce,  MD and 
Randall J. Kimple, MD, PhD  
 
 
Signed:  Date:  
 
 
Name:  Justine Yang Bruce,  MD 
 
Title:  Associate  Professor,  Department  of Medicine,  University  of 
Wisconsin School of Medicine and Public Health 
 
 
 
 
 
Signed:  Date:  
 
 
Name:  Randall  J. Kimple,  MD, PhD 
 
Title:  Associate  Professor,  Department  of Human  Oncology,  University  of 
Wisconsin School of Medicine and Public Health 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
4 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 TABLE OF CONTENTS   
 
PAGE 
STATEMENT  OF COMPLIANCE  ............................................................................................................. 2 
SIGNATURE  PAGE  ................................................................................................................................... 3 
TABLE OF CONTENTS  ............................................................................................................................. 4 
LIST  OF ABBREVIATIONS  ....................................................................................................................... 7 
PROTOCOL  SUMMARY  ......................................................................................................................... 10 
1 KEY ROLES  AND CONTACT  INFORMATION  .......................................................................... 13 
2 INTRODUCTION:  BACKGROUND INFORMATION  AND SCIENTIFIC  RATIONALE  ......... 17 
2.1 Rationale  ............................................................................................................................. 22 
2.2 Potential  Risks  and Benefits  ............................................................................................. 23 
2.2.1 Potential  Risks  ....................................................................................................... 23 
2.2.2 Potential  Benefits  .................................................................................................. 24 
3 OBJECTIVES  .................................................................................................................................. 24 
3.1 Study  Objectives  ................................................................................................................ 24 
3.2 Study  Outcome  Measures  ................................................................................................ 24 
3.2.1 Primary  Endpoint  .................................................................................................. 24 
3.2.2 Secondary  Endpoint  ............................................................................................. 25 
3.2.3 Exploratory  Endpoints  .......................................................................................... 25 
4 STUDY  DESIGN  ............................................................................................................................. 25 
4.1 Substudies  (if applicable)  .................................................................................................. 27 
5 STUDY  ENROLLMENT  AND WITHDRAWAL  ............................................................................ 27 
5.1 Subject  Inclusion Criteria  .................................................................................................. 28 
5.2 Subject  Exclusion  Criteria  ................................................................................................. 29 
5.3 Strategies  for Recruitment  and Retention ...................................................................... 30 
5.3.1 Subject  Remuneration ....................................................................................................... 30 
5.4 Treatment  Assignment  Procedures  ................................................................................. 31 
5.5 Subject  Withdrawal  ............................................................................................................ 31 
5.5.1 Reasons  for Withdrawal  ....................................................................................... 31 
5.5.2 Handling of Subject Withdrawals or Subject Discontinuation of Study 
Intervention ............................................................................................................ 31 
5.6 Premature  Termination or Suspension of Study  ............................................................ 32 
6 STUDY  INTERVENTION  ............................................................................................................... 32 
6.1 Study  Product  Description  ................................................................................................ 32 
6.1.1 Acquisition  .............................................................................................................. 33 
6.1.2 Formulation,  Packaging,  and Labeling  .............................................................. 33 
6.1.3 Product  Storage and Stability  .............................................................................. 33 
6.2 Dosage,  Preparation and Administration  of Study  Product  ......................................... 33 
6.2.1 Potential  adverse events  and precautions  ........................................................ 35 
6.3 Modification of Study  Product  Administration  for a Subject  ......................................... 37 
6.4 Accountability  Proced ures for the Study  Product  .......................................................... 38 
6.5 Assessment  of Subject  Compliance with Study  Product  Administration .................... 38 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
5 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 6.6 Concomitant  Medications/Treatments  ............................................................................. 38 
7 STUDY  SCHEDULE  ....................................................................................................................... 38 
7.1 Screening / Baseline Visit (Day  -28 to -1) ...................................................................... 39 
7.2 Intermediate  Visits  ............................................................................................................. 40 
7.3 Final  Study  Visit .................................................................................................................. 42 
7.4 Withdrawal  Visit .................................................................................................................. 42 
7.5 Unscheduled Visit .............................................................................................................. 42 
8 STUDY  PROCEDURES  /EVALUATIONS................................................................................... 43 
8.1 Study  Procedures/Evaluations  ......................................................................................... 43 
8.2 Laboratory  Procedures/Evaluations  ................................................................................ 44 
8.2.1 Clinical Laboratory  Evaluations  ........................................................................... 44 
8.2.2 Special  Assays or Procedures  ............................................................................ 44 
8.2.3 Specimen Preparation,  Handling,  and Storage ................................................ 45 
8.2.4 Specimen Shipment  ............................................................................................. 46 
9 ASSESSMENT  OF SAFETY  ......................................................................................................... 47 
9.1 Specification of Safety  Parameters  ................................................................................. 47 
9.1.1 Unanticipated Problems  ....................................................................................... 48 
9.1.2 Adverse Events  ..................................................................................................... 48 
9.1.3 Serious  Adverse  Events ....................................................................................... 48 
9.2 Time  Period and Frequency  for Event  Assessment  and Follow -Up ........................... 49 
9.3 Characteristics  of an Adverse Event  ............................................................................... 49 
9.3.1 Relationship to Study  Intervention  ...................................................................... 49 
9.3.2 Expectedness  of SAEs  ......................................................................................... 50 
9.3.3 Severity  of Event  ................................................................................................... 50 
9.4 Reporting Procedures  ....................................................................................................... 50 
9.4.1 Unanticipated Problem  Reporting to IRB and NIDCR  ..................................... 55 
9.4.2 Serious  Adverse  Event  Reporting to NIDCR  .................................................... 56 
9.4.3 Reporting of SAEs  and AEs to FDA ................................................................... 57 
9.4.4 Events  of Special  Interest  (if applicable)  ........................................................... 57 
9.4.5 Reporting of Pregnancy  ....................................................................................... 57 
9.5 Halting  Rules  ...................................................................................................................... 57 
10 STUDY  OVERSIGHT  ..................................................................................................................... 58 
11 CLINICAL  SITE MONITORING  .................................................................................................... 59 
12 STATISTICAL  CONSIDERATIONS  ............................................................................................. 60 
12.1 Study  Hypotheses  .............................................................................................................. 60 
12.2 Sample Size Considerations  ............................................................................................ 60 
12.3 Planned Interim  Analyses  (if applicable)  ........................................................................ 61 
12.4 Final  Analysis  Plan  ............................................................................................................ 61 
13 SOURCE  DOCUMENTS  AND ACCESS TO SOURCE  DATA/DOCUMENTS  ...................... 61 
14 QUALITY  CONTROL  AND QUALITY  ASSURANCE  ................................................................ 62 
14.1 Monitoring,  Auditing,  and Data  Quality  Control  and Assurance  Measures  by 
Study  Team ......................................................................................................................... 62 
15 ETHICS/PROTECTION OF HUMAN SUBJECTS  ..................................................................... 63 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
6 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 15.1 Ethical  Standard ................................................................................................................. 63 
15.2 Institutional  Review Board ................................................................................................ 63 
15.3 Informed  Consent  Process ............................................................................................... 63 
15.4 Exclusion  of Women,  Minorities,  and Children  (Special  Populations)  ........................ 64 
15.5 Subject  Confidentiality  ....................................................................................................... 64 
15.6 Future  Use of Stored  Specimens  and Other  Identifiable Data  .................................... 65 
16 DATA  HANDLING  AND RECORD KEEPING  ............................................................................ 65 
16.1 Data  Management  Responsibilities  ................................................................................. 66 
16.2 Data  Capture  Methods  ...................................................................................................... 66 
16.3 Types  of Data  ..................................................................................................................... 66 
16.4 Schedule and Content  of Reports  ................................................................................... 66 
16.5 Study  Records  Retention .................................................................................................. 66 
16.6 Protocol  Deviations  ............................................................................................................ 67 
17 PUBLICATION/DATA  SHARING  POLICY  .................................................................................. 67 
18 LITERATURE  REFERENCES  ...................................................................................................... 68 
APPENDICES  ........................................................................................................................................... 73 
APPENDIX A: SCHEDULE  OF EVENTS  ............................................................................................. 74 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
7 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 LIST OF ABBREVIATIONS  
 
 
 
Abbreviation  Definition  
5-FU 5-fluorouracil  
AE Adverse Event/Adverse Experience  
ANC absolute  neutrophil  count  
ALK anaplastic  lymphoma  kinase  
ALT alanine  aminotransferase  
AST aspartate  aminotransferase  
CBC complete  blood  cell count  
CCND -1 cyclin D1 
CFR Code  of Federal  Regulations  
CI confidence interval  
cm Centimeter  
CNS Central  nervous  system  
CRC  Clinical  Research  Committee  (CRC)  
CRF case report form 
CT computed tomography  
CTC Common  Toxicity  Criteria  
CTCAE  (NCI)  Common  Terminology  Criteria  for Adverse  Events  
CTX cetuximab  
CTXR  cetuximab resistant  
CTXS  cetuximab sensitive  
CVA cerebrovascular accident  
dL Deciliter  
DLT dose  limiting  toxicity  
DOT Disease  Oriented  Team  
DSMC  Data  Safety  Monitoring  Committee  
DSMS  Data  and Safety  Monitoring  System  
eCRF  electronic  case  report  form 
ECOG  Eastern  Cooperative  Oncology  Group  
EGFR  epidermal  growth  factor  receptor  
FDA Food  and Drug  Administration  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
8 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
  
FGFR  fibroblast  growth  factor  receptor  
GCP  Good  Clinical  Practice  
HCl hydrochloric  acid 
HER human  epidermal  growth  factor  receptor  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
HIV human  immunodeficiency  virus 
HNSCC  head  and neck  squamous  cell carcinoma  
HPV human  papillomavirus  
hr Hour  
ICF Informed  Consent  Form  
ICH International  Conference  on Harmonisation  
IND Investigational  New Drug  Application  
IRB Institutional  Review  Board  
IUD Intra uterine  device  
IV Intravenous  
kg Kilogram  
lb Pound  
mg Milligram  
min Minute  
mL Milliliter  
mm3 cubic millimeters  
MRI magnetic resonance imaging  
mTOR  mechanistic  target of  rapamycin  
NCI National  Cancer  Institute  
NDC  National  Drug  Code  
NIDCR  National  Institute  of Dental  and Craniofacial  Research  
NIH National  Institutes  of Health  
NS Normal  saline  
OHRP  Office  for Human  Research  Protections  
OS overall  survival  
PDX patient -derived  xenograft  
PI Principal Investigator  
PHI Protected  Health  Information  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
9 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
  
PI3K  phosphatidylinositol  3-kinase  
PSR Protocol Summary Report  
PTEN  phosphatase  and tensin  homolog  
RECIST  Response  Evaluation  Criteria  in Solid  Tumors  
RTK receptor tyrosine kinase  
SAE Serious Adverse Event/Serious Adverse Experience  
SCC squamous cell carcinoma  
SFK Src Family Kinase  
SOC  standard  of care 
SOP Standard Operating Procedure  
ULN upper  limit of normal  
UP unanticipated  problem  
UPIRSO  unanticipated  problems  involving  risk to subjects  or others  
US United  States  
USP United  States  Pharmacopeia  
UW University  of Wisconsin  
UWCCC  University  of Wisconsin  Carbone  Cancer  Center  
WHO  World  Health  Organization  
WOCP  women  of childbearing  potential  
wt Weight  
  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
10 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 PROTOCOL SUMMARY  
 
Title:  A window  of opportunity  trial of cetuximab in patients  with head and 
neck squamous cell carcinoma (HNSCC): examining the role of 
receptor tyrosine kinase AXL in HNSCC therapy resistance  
Précis:  This is a window of opportunity trial evaluating the hypothesis that AXL levels correlate with clinical response to cetuximab i n head and 
neck  patients.  Patients  with head and neck  squamous  cell carcinoma 
who are scheduled to undergo surgical resection of their tumor and 
are candidates for cetuximab chemotherapy are eligible to 
participate.  
 
 
Objectives:  Primary:  
1. To test the hypothesis  that low AXL correlates  with clinical 
response to cetuximab in head and neck cancer patients  
 
 
Secondary:  
1. To further  describe the safety  of pre-operative administration 
of cetuximab  
 
Correlative:  
1. To correlate  AXL expression with change  in Ki67 following 
cetuximab in HNC patients  
2. To examine  other  putative  markers  of cetuximab sensitivity 
such as HER3 and change in circulating tumor cells  
3. To establish the first panel  of patient -derived  xenografts  from 
patients with known sensitivity or resistance to cetuximab 
 
 
Population:  36 adult patients (≥ 18 years) of either sex and of any race or 
ethnicity,  who have  a biopsy  proven,  squamous  cell carcinoma of the 
head and neck, are candidates for pre- operative therapy with 
cetuximab, and are scheduled for res ection of the tumor.  
Patients  with advanced  cutaneous  head  and neck  squamous  cell 
carcinoma are excluded.  
 
Phase:  Window  of Opportunity  Study  
Number  of Sites:  1 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
11 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Description of 
Intervention:   
Following informed consent, tumor tissue from the research biopsy 
and a blood draw for circulating tumor cells will be obtained. The 
patient will then receive two weekly doses of pre -operative 
cetuximab  during  the interval  between  diagnostic  biopsy  and surgery 
ensuring that no delay in standard of care (SOC) will occur.  
For dose #1, patients will receive cetuximab 400 mg/m2 via 
intravenous infusion over 2 hours (maximum infusion rate 10 
mg/min)  as per the standard of care loading regimen for cetuximab 
monotherapy.1 
For dose #2, patients will receive cetuximab 250 mg/m2 via 
intravenous  infusion over 1 hour (maximum infusion  rate 10 mg/min) 
as per the standard of care dosing regimen for cetuximab monotherapy.
1 
At the time of surgery, another blood draw will be obtained for 
analysis  of circulating  tumor  cells,  and a portion of the resected 
tumor will be obtained for study analysis.  
Correlative studies will include the measurement of proteins hypothesized to be involved in cetuximab resistance such  as AXL, 
Ki67, EGFR, and HER3 expression from both the biopsy and the surgical  specimen.  Blood will be analyzed for correlative analysis  of 
circulating tumor cells. Tissue from the research biopsy will be utilized for patient -derived xenograft (PDX) development.  
 
Study Duration:  30 months  
 
Subject  Participation 
Duration:  
Estimated Time  to 
Complete Enrollment:  13-16 months  
 
18 months  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
12 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Schematic of Study  Design:  
The primary objective of this window of opportunity study is to test the hypothesis that 
low AXL expression correlates with clinical response to cetuximab in head and neck cancer  patients.  The secondary  objective  of this study  is to further  describe  the safety of 
pre-operative administration of cetuximab. It is estimated that from the time of 
diagnosis/consult to resection of tumor is approximately 4- 6 weeks. There is no 
absolute timeframe for study procedures to occur, although all protocol activities must  
be completed prior to resection.  
 
 
This is a window of opportunity  trial to study  AXL and CTX in HNSCC patients.  HNSCC 
patients who will undergo surgery will be identified. The tumor will be measured by the treating physician. A research biopsy will be taken and scored for Ki67 and proteins hypothesized to be involved in CTX resistance, such as AXL, EGFR and HER3. A section of the biopsy will be used for PDX development. A blood draw will be taken for circulating tumor cell analysis. Patients will receive two doses of cetuximab. Safety will be evaluated  and blood will be collected for quantification  of circulating tumor cells prior 
to resection. Remnant tissue from the resected tumor will be stained for Ki67 and compared to pre- treatment tumors. It will also be analyzed for proteins hypothesized to 
be involved  in CTX resistance,  such  as AXL,  EGFR  and HER3.  Patients  will have blood 
draws for circulating tumor cells at 3 follow up timepoints: one month post -surgery, 3 
months post definitive care and 12 months post definitive care. Patients will then continue on to standard of care.  

A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
13 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 1 KEY ROLES  AND CONTACT  INFORMATION  
 
Principal 
Investigator:  
 
   
 
  
 
NIDCR Medical 
Monitor:  
NIDCR Program 
Official:  
Clinical Site 
Investigators:  Justine Yang Bruce,  MD 
University  of Wisconsin Carbone Cancer  Center 
WIMR Room 3019  
1111 Highland Avenue  
Madison,  WI 53705  
Phone:  (608)  262-4961  
jybruce@medicine.wisc.edu 
 
Randall  J. Kimple,  MD, PhD 
University  of Wisconsin Carbone Cancer  Center 
WIMR Room 3107  
1111 Highland Avenue  
Madison,  WI 53705  
Phone:  (608)  265-9156  
rkimple@humonc.wisc.edu  
Kevin McBryde, MD  
 
Chiayeng Wang,  PhD 
 
Justine Yang Bruce,  MD 
University  of Wisconsin Carbone Cancer  Center 
WIMR Room 3019  
1111 Highland Avenue  
Madison,  WI 53705  
Phone:  (608)  262-4961  
jybruce@medicine.wisc.edu 
 
Randall  J. Kimple,  MD, PhD 
University  of Wisconsin Carbone Cancer  Center 
WIMR Room 3107  
1111 Highland Avenue  
Madison,  WI 53705 
Phone:  (608)  265-9156 
rkimple@humonc.wisc.edu 
 
Institutions:  University  of Wisconsin- Madison  
Contact  Person/Local  Investigator:  
Justine Yang Bruce,  MD 
University  of Wisconsin Carbone Cancer  Center 
1111 Highland Avenue, WIMR 3109  
Madison,  WI 53705  
Phone:  (608)  262-4961  
jybruce@medicine.wisc.edu 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
14 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Other Key 
Personnel:  Co-Investigators  
Clinical 
 
Greg Hartig, MD Department  of Surgery  
Division  of Otolaryngology -Head & Neck  Surgery  
University  of Wisconsin  School  of Medicine  and Public  Health 
600 Highland Avenue, MC 7375  
Madison, WI 53792  
Phone:  (608)  265-8207  
hartig@surgery.wisc.edu 
 
Timothy  M. McCulloch,  MD 
Department of Surgery  
Division  of Otolaryngology -Head & Neck  Surgery  
University  of Wisconsin  School  of Medicine  and Public  Health 
600 Highland Avenue, MC 7375  
Madison, WI 53792  
Phone:  (608)  263-0192  
mccull@surgery.wisc.edu  
 
Tiffany Glazer, MD Department  of Surgery  
Division  of Otolaryngology -Head & Neck  Surgery  
University  of Wisconsin  School  of Medicine  and Public  Health 
600 Highland Avenue, MC 7375  
Madison, WI 53792  
Phone:  (608)  265-8504  
glazer@surgery.wisc.edu 
Aaron Wieland, MD 
Department  of Surgery  
Division  of Otolaryngology -Head & Neck  Surgery  
University  of Wisconsin  School  of Medicine  and Public  Health 
600 Highland Avenue, MC 7375  
Madison, WI 53792  
Phone:  (608)  262-2876  
wieland@surgery.wisc.edu  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
15 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
  
 
Seth Dailey, MD 
Department  of Surgery  
Division  of Otolaryngology -Head & Neck  Surgery  
University  of Wisconsin  School  of Medicine  and Public  Health 
600 Highland Avenue, MC 7375  
Madison, WI 53792- 3284 
Phone:  (608)  265-8207  
dailey@surgery.wisc.edu 
 
Paul Harari,  MD 
Department  of Human Oncology  
University  of Wisconsin  School  of Medicine  and Public  Health 
K4/336, Clinical Science Center  
600 Highland  Avenue,  MC 3674 
Madison, WI 53792  
Phone:  (608)  263-5009  
harari@humonc.wisc.edu 
 
Scientific  
Deric  Wheeler,  PhD 
Department  of Human Oncology  
University  of Wisconsin  School  of Medicine  and Public  Health 
WIMR Room 3159  
1111 Highland Avenue  
Madison, WI 53705  
Phone:  (608)  263-3611  
dlwheeler@wisc.edu  
 
Seungpyo Hong, PhD 
Pharmaceutical  Sciences  Division  
University  of Wisconsin  School  of Pharmacy 
Rennebohm Hall  
777 Highland  Avenue  
Madison, WI 53705 
Seungpyo.hong@wisc.edu  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
16 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Biostatisticians  
Menggang Yu, PhD 
University  of Wisconsin  
Department  of Biostatistics and Medical  Informatics 
K6/436 Clinical Science Center  
600 Highland  Avenue  
Madison, WI 53792  
Phone:  (608)  261-1988  
meyu@biostat.wisc.edu 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
17 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 2 INTRODUCTION:  BACKGROUND INFORMATION  AND SCIENTIFIC  RATIONALE  
Head  and neck  squamous  cell carcinoma,  and identification  of potentially 
actionable mutations  
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide with over 600,000 new cases diagnosed annually.2 In the United States 
alone,  in 2017,  there were  approximately  63,000  newly  diagnosed HNSCC,  with roughly 
13,300 deaths.3 
 
Head and neck cancer is a complex heterogeneous disease that arises from various sites including the oral cavity, tongue, pharynx, larynx and salivary glands. Over 90% of tumors that originate in the oropharyngolaryngeal axis are squamous cell carcinoma (SCC). Treatment for HNSCC patients includes surgery, radiation and chemotherapy in various  combinations.  Cure  rates  have improved only marginally  over the last 30 years.
4 
Typically, local or regional disease recurs in 30% of patients, and distant metastases appear  in 25% of patients.  The 5-year overall  survival  rate is 40%.
5 Despite  the ability  to 
cure localized and locally advanced disease, there is a significant unmet ne ed for 
treatment of patients who undergo surgical resection of their head and neck cancer.  
 
To identify molecular driver mutations in head and neck squamous cell carcinoma, the 
Cancer Genome Atlas Research Network profiled 279 HNSCC tumors and identified a 
series  of mutations  and amplifications.  However,  only a handful  of identified oncogenes 
in head and neck squamous cell carcinoma are immediately targetable with agents in 
clinical development, namely epidermal growth factor receptor (EGFR), fibroblast 
growth factor receptor (FGFR), MET, cyclin D1 (CCND1) and phosphatidylinositol 3-  
kinase (PI3K)  CA13.6 The identification of these novel mutations and their ability to be 
effectively targeted expands the potential future treatment armamentarium for patients with head and neck squamous cell carcinoma, but the role they play in cetuximab resistance is  unknown.  
 
Cetuximab  
In 2006, the FDA approved cetuximab, a monoclonal antibody against the EGFR, in the treatment  of HNSCC.  The addition  of cetuximab to standard  radiation improves  absolute 
survival rates for newly diagnosed head and neck squamous cell carcinoma patients by approximately 10%
7,8 and is also valuable in the metastatic/recurrent setting where 
approximately 36% of patients experience response to cetuximab based combinati on 
therapy (vs. 20% to standard therapy).9 
 
Although cetuximab offers a significant advance for many patients with head and neck squamous cell carcinoma, nearly two- thirds of EGFR expressing patients do not 
respond to cetuximab -based therapy.  The response rate to cetuximab  alone for patients 
with metastatic head and neck squamous cell carcinoma is only 10- 20%, highlighting 
the need for improved treatments.
10,11 Virtually all patients who initially respond 
eventually become refractory to cetuximab. Intrinsic  and acquired resistance to 
cetuximab is therefore a significant clinical problem in the treatment of HNSCC.12 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
18 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Enhancing  the effectiveness  and survival  impact  of cetuximab  would  be highly  valuable 
for the head and neck squamous cell cancer patient population.  
 
Primary  head  and neck  tumor  sites  and cetuximab  usage  
FDA approval  has been  issued  for cetuximab  (CTX) in the following  settings:  
i) locally  or regionally  advanced squamous  cell carcinoma of the head  and neck 
in combination with radiation therapy,  
ii) recurrent locoregional disease or metastatic squamous cell carcinoma of the 
head and neck  in combination with platinum -based therapy  with 5-fluorouracil 
(5-FU), and  
iii) recurrent  or metastatic  squamous  cell carcinoma  of the head  and neck 
progressing after platinum -based therapy.  
 
Cetuximab is approved for squamous cell carcinomas of all head and neck sites. This 
approval includes usage in the adjuvant, recurrent or metastatic settings. In the landmark  study  of cetuximab  in combination with concurrent  radiotherapy  for treatment 
in the locoregional setting, 424 patients were randomized. Sites of primary tumor 
represented by those 424 patients included oropharynx, hypopharynx, and larynx. A predominance of oropharyngeal primaries was enrolled with 56% of patients randomized to the conc urrent cetuximab plus radiotherapy arm having oropharyngeal 
primaries. Sixty three percent (63%) of patients within the radiotherapy monotherapy arm had oropharyngeal primaries.
8 
 
In the EXTREME trial that led to approval of cetuximab in combination with 5- FU and 
platinum chemotherapy, 442 patients were enrolled with primary tumor sites including the oral cavity, oropharynx, hypopharynx, larynx, and a category of “other” unspecified squamous  cell carcinomas  of the head and neck.  Again,  the predominant  prima ry tumor 
site was the oropharynx with 36% of patients randomized to chemotherapy plus cetuximab having primary oropharyngeal cancer. Thirty one percent (31%) of patients randomized to chemotherapy without cetuximab had an oropharyngeal primary.  
Squamous  cell carcinomas  originating from “other” head and neck  sites accounted for 4 
and 10% of primary  tumors  within  the chemotherapy  plus cetuximab and chemotherapy 
alone arms respectively.
9 
 
In the single- arm phase II study  leading to approval  of cetuximab  monotherapy  after 
platinum  failure  in the recurrent  or metastatic  setting, 103 patients  were  enrolled.  Of 
those patients, pharyngeal primaries were again the most commonly enrolled, accounting for 38% of enrolled patients. Laryngeal primaries acc ounted for 20%.  
Primary paranasal sinus cancers accounted for 3%, while “other” and “unclassifiable” sites accounted for the remaining  39% of enrollment.
10 Other  trials  studying 1-3 weeks 
of anti -EGFR therapy demonstrated a significant decrease in tumor si ze in operable 
head and neck squamous cell carcinoma.13,14 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
19 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Evidence for the usage  of cetuximab  in advanced cutaneous  squamous  cell carcinomas 
is lacking overall. As such, treatment of advanced cutaneous carcinomas will be 
excluded from this study.  
 
Mechanisms of resistance 
As the only molecular targeting agent approved in head and neck cancer therapy, detailed understanding of how hea d and neck squamous cell 
cancers become refractory to cetuximab therapy is central to further refining the impact of this promising molecular  agent  and its clinical efficacy.  Furthermore, 
development of biomarkers leading to the identification of patients who will be responsive to 
cetuximab therapy is of high significance.  
 
Resistance to cetuximab has been explored, and several mechanisms of resistance have been reported including: altered angiogenesis,
15-17 
increased EGFR activity,18 increased expression o f 
human  epidermal  growth factor  receptor  (HER)  family 
ligands,19,20 decreased EGFR degradation,18,21 
epithelial to mesenchymal shift,22 phosphatase and 
tensin homolog (PTEN) degradation,23 a role for the 
nuclear EGFR signaling network20 and activation of 
HER3.18,24- 29 Some tumors are intrinsically resistant  
to CTX and demonstrate no response to even  the first 
dose of drug.10 The mechanism of resistance is not 
known. Treatment of two doses of CTX has not been shown to lead to clinical resistance to therapy.  
HER3 is a member of the EGFR family of receptor tyrosine  kinases (RTKs)  and is unique in the absence 
of intrinsic kinase activity. Despite this lack of kinase 
activity, HER3 is phosphorylated by hetero-  
dimerization with other family members.
30 HER3 has 
multiple binding sites in the cytoplasmic tail for the  
regulatory subunit of phosphatidylinositol 3- kinase (PI3K) to be rec ruited and thus 
transmit signals to the PI3K/Akt/ mechanistic target of rapamycin (mTOR) survival pathway.
31,32 Recent  work  by several  laboratories,  has found  a strong  role for HER3 
activity in therapeutic resistance.24-30,33 (Figure 1)  
 
To identify drivers of CTX resistance in HNSCC, University of Wisconsin (UW) investigators  have utilized  HNSCC human tumor  specimens,  patient -derived xenografts 
(PDXs) and a series of acquired and intrinsically resistant in vitro and in vivo model  

A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
20 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 systems.18,33- 37 Investigation of these models  to isolate  molecular  mechanisms  of 
cetuximab resistance has generated several significant findings.  
 
Tissue analysis of a head and neck squamous cell carcinoma patient cohort (n=63) 
identified that the receptor tyrosine kinase AXL was overexpressed in both human papillomavirus (HPV) positive and HPV -negative head and neck squamous cell 
carcinoma tumor s and was significantly  associated with higher  pathologic  grade,  distant 
metastases, and shorter relapse free survival.
37 Cetuximab- resistant head and neck 
squamous cell carcinoma patient -derived xenografts, relative to cetuximab- sensitive 
(CTXS) tumors, e xpressed significantly elevated levels of total and activated AXL.35,37 
HPV status does not predict CTX response.38 
 
Models ( in vitro and de novo (in vivo)) of acquired resistance showed increased 
expression and activity of AXL.35,37,39 Models of intrinsic ally resistant HNSCC lines 
showed increased AXL expression and activity.35,37 Genetic ablation or therapeutic 
inhibition (antibody or small molecule inhibitors) of AXL led to increased sensitivity to 
cetuximab,  both in vitro and in vivo.35,37 Overexpression of AXL in cetuximab  sensitive 
HNSCC lines rendered them resistant, whereas a kinase dead AXL retained 
sensitivity.35 Proteomic analysis within cetuximab resistant models indicated a strong 
linkage between AXL, Src Family Kinase (SFK) and HER 3 activity; a novel pathway 
leading  to therapeutic escape from cetuximab therapy driven by AXL in HNSCC (data 
not shown).  
 
To correlate AXL expression with clinical response to CTX, we will use both change in tumor  dimensions  as measured  by treating  physician  and change  in Ki67 expression (% 
cells with Ki67 staining).  Ki67 staining has been  used  successfully in HNSCC (and other 
tumor types) window trials as a surrogate marker of response to cetuximab and to assess the pharmacodynamic effects of novel target ing agents and can serve as a 
surrogate for clinical response.
14,40- 50 
 
Circulating  Tumor  Cells  as a predictive  biomarker  for HNSCC  
Circulating  tumor  cells are tumor  cells that detach from the primary  tumor  or metastasis 
and circulate in the bloodstream of a cancer patient. Circulating tumor cells are extremely rare and are heterogeneous,
51 presenting a tremendous challenge for 
efficient, clinically significant detection of circulating tumor cells.  
 
Advances in  biomedical  engineering  have led to the development  of capture devices  for 
circulating tumor cells. Some of the most promising devices generally combine immunocytochemical  capture with microfluidic  devices  to capture circulating  tumor  cells. 
CellSearch is t he only FDA -approved system for clinical use (metastatic breast, 
prostate, and colorectal cancer). In these diseases, the presence and the number of circulating tumor cells have been shown to be prognostic for development of metastatic disease.
52 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
21 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 However, the clinical use of circulating tumor cells has been limited due to low 
sensitivity of  current circulating tumor cell capture technology. For example,  the only 
reports of circulating tumor cells in HNSCC involved CellSearch, and they were only able to detect circulating tumor cells in 1 out of 3 patients.
53 Hence, there has been 
strong  interest  in the development  of more  sensitive  devices to capture and evaluate 
circulating tumor cells as predictive biomarkers for cancer treatment.  
 
Highly Sensitive CTC Capture Assay  
Utilizing  several  biomimetic  technologies  at the University  of Wisconsin  (UW),  we have 
developed a novel and highly sensitive assay to capture circulating tumor cells, as illustrated in Fig. 2. First, it has a biomimetic surface that induces cell rolling. The biofunctional surface is engineered by immobilizing selectins which can engage cell surface receptors to induce cell rolling.
54 The cell  rolling effect slows down the velocity 
of tumor cells and in turn improves capture specificity.54 
 
Another  unique feature  of this device  is application of nanotechnology  to cell capturing. 
By utilizing a flexible dendrimer nanoparticle, the device enables multivalent binding between antibody -functionalized dendrimers and tumor cells.
55 Multivalent binding can 
improve binding affinity by as much as 106 times, thus improving sensiti vity to capture 
circulating tumor cells.56 
 
Lastly,  the circulating tumor  cells assay  can incorporate multiple  antibody  ligands  for 
tumor  cell capture.56 This enables  the capture of circulating  tumor  cells with different 
surface biomarkers, such as cells t hat have undergone epithelial -mesenchymal 
transition.  
 
In prior work at the University of Wisconsin, the surfaces of the highly sensitive assay captured a high number of circulating tumor cells (221 circulating tumor cells per mL of blood, ranging from 36 to 1,135) from all 27 patients recruited
57, which is significant 
considering that CellSearch could only detect circulating tumor cells from 1 of every three HNSCC patients.
53 Importantly, when the UW results were compared to the 
previously  reported  clinica l data from similar  groups  of cancer  patients  with comparable 
or worse cancer stages using CellSearch,53,58 -60 the UW surfaces apparently achieved 
three orders of magnitude higher counts of circulating tumor cells than CellSearch (1,613 vs. 4.7 circulating tumor cells in 7.5 mL of blood). One can argue that the cells we captured could be non- circulating tumor cell s; however, the UW device captured 
only 2.1 circulating tumor cells (could be epithelial cells) per mL from healthy donors’ blood (n=8), mitigating the concern of potential false- positive detection.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
22 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 
 
 
 
Flowing  cells:  RBCs   
Flow  direction  
 
 
Rolling  cells:  CTCs  and leukocytes    
 
 
 
Trapped CTC 
 
Microfluidic  channel  surface coated  with micro -patterned domains  
 
Fig 2. A schematic diagram of CTC capture on a 
micropatterned surface using iterative cell rolling (E -selectin: 
red) and multivalent  stationary  adhesion (antibody:  green).  The 
inset diagram represents immobilized antibody molecules (e.g. 
aEpCAM, aPD -L1, and aEGFR) through a flexible polymer 
nanolinker  (dendrimer  and PEG:  blue)  by which  the multivalent 
effect  can be achieved through locally  concentrated  antibodies.  
 
 
 
Overall Goal  and Importance  of the Study  
This clinical trial seeks  to obtain baseline tissue from a research biopsy  and circulating 
tumor cells to determine whether AXL expression pre- treatment correlates to clinical 
outcomes after two doses of cetuximab. The importance of this study is to describe if 
AXL expression can be used as a biomarker to predict clinical response to cetuximab treatment.  
 
2.1 Rationale  
Despite the broad advancement of molecularly targeted therapies across the oncology spectrum, cetuximab remains the only approved molecular targeted drug for the treatment  of patients  with head and neck  squamous  cell carcinoma. 
Cetuximab improves 5 -year overall survival when combined with radiation in  
the curative treatment setting from 36.4% with radiation therapy alone to 45.6% with the combination.
7,8 When combined with chemotherapy in the 
metastatic/recurrent setting, cetuximab improves overall survival by 2.7 months.
9 This survival impact is modest, however, and the response rate to 
cetuximab alone for patients with metastatic head and neck squamous cell carcinoma is only about 10- 20%, highlighting the need for improved 
treatments.
10,11 Enhancing the effectiveness and survival impact of cetuximab 
would be highly valuable for the head and neck squamous cell carcinoma patient population.  
 
Preliminary  data35,37 suggest  a role for AXL in cetuximab resistance in HNSCC, 
and the potential for AXL to serve as a functional biomarker for cetuximab response in humans. Targeting AXL has the potential to re- sensitize tumors to 
cetuximab therapy.  
Circulating  tumor  cell (rolling  and trapped) 
Leukocyte (White blood cell)  
Red blood  cell 
E-selectin coated region 
Antibody  coated  microdomains  
Antibody  (aEpCAM,  aHER,  aEGFR,  etc.) 
Poly(amidoamine)  dendrimer 
Poly(ethylene glycol) linker  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
23 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 In this study,  we propose  a window  of opportunity  trial to evaluate levels  of AXL 
in tumors pre-  CTX treatment and compare t hat to the clinical response and 
changes in the size of the primary tumor mass or lymph nodes. Study 
participants will be treated with two doses of cetuximab given intravenously as per the standard of care regimen, except that the cetuximab will be adminis tered during  the interval  between diagnostic  biopsy  and surgery  instead 
of post -surgery. For dose #1, patients will receive a loading dose of cetuximab 
400 mg/m2 via intravenous infusion over 2 hours as per the standard of care loading dose regimen for cet uximab monotherapy. For dose #2, patients will 
receive cetuximab 250 mg/m2 via intravenous infusion over 1 hour as per the standard of care regimen for cetuximab monotherapy.  
 
We plan to use a portion of the pre- cetuximab treatment tumor samples to  
study c orrelative objectives of the role of AXL in cetuximab resistance and to 
create the first cohort of patient derived xenografts with known sensitivity or resistance to cetuximab treatment. These will be used to evaluate if targeting AXL in cetuximab resistant  patient -derived xenografts  will re-sensitize  the tumor 
to cetuximab. In addition, blood samples will be collected to evaluate whether circulating tumor cells, among other biomarkers, correlate with response to treatment.  
 
We hypothesize that low AXL correlates with clinical response to CTX in HNSCC.  Furthermore,  we hypothesize  that circulating  tumor  cells correlate with 
response to treatment and that the AXL/HER3 circuit can be used as a biomarker to predict cetuximab resis tance in HNSCC.  
 
2.2 Potential  Risks and Benefits  
2.2.1  Potential Risks  
Cetuximab- related risks include infusion reactions, acneiform rash, and in rare 
cases cardiopulmonary arrest and or interstitial lung disease (see details in section 6.2.1.) Other risks include those related to the research biopsy 
(bleeding and infection  at the site where the needle is inserted,  brief pain during 
the procedure) and blood draws (bruising, swelling at the injection site, dizziness and lightheadedness), as well as loss of confidenti ality. Other study - 
related procedures that may introduce “risks” to study participants include:  
 
1) Urine/serum  pregnancy  tests;  
2) Premedication with diphenhydramine/acetaminophen prior to Cetuximab 
infusions;  
3) Potential  medications  used to treat Cetuximab- related rashes 
(Hydrocortisone, Doxycycline, Clindamycin);  
4) Risks  of developing and/or  correction  of electrolyte disturbances  due to 
Cetuximab infusion  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
24 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 2.2.2  Potential Benefits  
There may be clinical benefit to the two administrations of cetuximab prior to 
surgery. Preliminary preclinical data35,37 suggest a role for AXL in cetuximab 
resistance in head and neck squamous cell carcinoma. AXL may potentially 
serve as a functional biomarker for cetuximab response in humans. Targeting 
AXL has the potential to resensitize tumors to cetuximab therapy. Treatment 
with two doses of cetuximab may offer clinical benefit including decreasing the 
tumor volume of the cancer to allow for easier resection at the time of surgery. Other  benefits  may include a predictive response that may determine  sensitivity 
of a patient’s cancer to systemic treatment.  
 
3 OBJECTIVES  
 
3.1 Study Objectives  
 
Primary:  To evaluate the hypothesis  that low AXL correlates  with clinical 
response to cetuximab in head and neck cancer patients  
 
Secondary:  To further  describe the safety  of pre-operative administration of 
cetuximab  
 
Correlative:  
1. To correlate AXL expression with change in Ki67 following  cetuximab  in 
HNC patients  
2. To examine other  putative markers  of cetuximab  sensitivity  such  as HER3 
and change in circulating tumor cells and other biomarkers  
3. To establish  the first panel  of patient -derived xenografts  from patients  with 
known sensitivity or resistance to cetuximab  
 
 
3.2 Study Outcome Measures 
3.2.1  Primary  Endpoint  
The objective response rate (ORR) measured by clinical examination and clinical measurements  at the time of diagnosis  and within  48 hours  prior to 
surgery  
This objective is to compare levels of AXL prior to CTX treatment to the clinical response and changes in the size of the primary tumor mass or lymph nodes. Patients will have their squamous cell carcinoma (either primary  site or nodal  metastases)  measured in centimeters  by the clinical 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
25 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 team via clinical measurement at two timepoints: 1) the time of diagnosis 
(pre- CTX)  and 2) after treatment  with 2 doses  of cetuximab and within  48 
hours prior to surgery (post -CTX).  
 
3.2.2  Secondary  Endpoint  
The rate of hospital re- admissions for wound care or surgical complications 
attributed to cetuximab (such as fistula  or deep  cellulitis)  within  28 days  after 
surgery  
 
Although the use of cetuximab pre- operatively has been studied in a pre- 
operative trial14, this clinical trial will expand upon this information to further 
evaluate any other complications during surgery due to pre- operative 
cetuximab. We will also plan a descriptive analysis of all AEs and SAEs 
associated with pre- operative cetuximab.  
 
3.2.3  Exploratory  Endpoints  
3.2.3.1  Change in Ki67 from pre- versus post-cetuximab treated  tumors  and its 
correlation with levels of AXL expression pre- cetuximab treatment  
3.2.3.2  Correlation of measures of putative markers of cetuximab sensitivity, 
including protein,  RNA,  circulating  tumor  cells with cetuximab response, 
measured by Ki67  
 
3.2.3.3  Establishment  of patient -derived  xenografts  with known 
sensitivity/resistance to cetuximab  
 
4 STUDY  DESIGN  
This clinical trial is a single- site, single arm, open  label,  window  of opportunity  study  for 
patients  with squamous  cell carcinoma  of the head and neck. Subjects  (targeted  N=36) 
are patients who have biopsy -proven, squamous cell carcinoma of the head and neck, 
excluding advanced cutaneous head and neck squamous cell carcinoma, who are 
anticipated to undergo surgical resection of the tumor, and who are candidates for cetuximab pre- operative therapy. Patients with newly diagnosed cancer or those who 
present with recurrent disease are eligible for this trial. All patients will undergo a research biopsy (in clinic or at the time of panendoscopy —not standard of care) and a 
staging workup with cross -sectional imaging of the neck (standard of care).  
 
Research- related Biopsies  and Blood  Draws  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
26 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Research- related procedures include a separate research biopsy of the tumor at the 
time of the diagnostic biopsy for analysis of Ki67, putative markers of CTX sensitivity, 
and research- related blood draws for collection of circulating tumor cells at five 
timepoints: screening visit, within 24 hours prior to surgery, and at follow -up visits: 
approximately 1 month post -surgery, as well as approximately 3 and 12 months post 
definitive care. The tissue obtained for research biopsy will be placed in culture medi a 
or saline and provided to the biologic correlate study team. If pathology confirms a diagnosis other than HNSCC, the patient will be removed from the study, and the research biopsy tissue will be released to the University of Wisconsin Translational Science BioCore (TSB) Biobank. If the clinical biopsy is inconclusive, the research 
tissue will be released  back  to University  of Wisconsin Surgical  Pathology  department  to 
aid in a clinical diagnosis. The research- related blood draws will be given directly to the 
biologic correlate study team for quantification of circulating tumor cells and/or other biomarkers.  
 
Cetuximab Administration  in the Pre-operative Setting  
Cetuximab is an FDA approved chemotherapy agent for the treatment of (a) locally or regionally  advanced squamous  cell carcinoma  of the head and neck  in combination  with 
radiation therapy, (b) recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum -based therapy with 5- FU, 
and (c) recurrent or metastatic squamous cell carcinoma of the head and neck progres sing after platinum -based therapy. Treatment with cetuximab prior to surgical 
resection is considered the investigational portion of this study, as neoadjuvant cetuximab is not considered standard of care. However, treatment with cetuximab as a monotherapy  may offer a benefit to patients as cetuximab is a known and approved 
chemotherapy agent for the treatment of head and neck cancer. In patients with recurrent and/or metastatic HNSCC with progression on platinum -based chemotherapy, 
those patients who were treated with cetuximab monotherapy had overall response rates  from 10-13% and disease control  rates  from 46-56%.
61 Although  surgical  resection 
will offer definitive treatment for local HNSCC, use of neoadjuvant cetuximab may offer disease response such as shrinkage of the tumor that may offer improved surgical resection.  
Cetuximab will be given twice via IV infusions at pre- specified doses within a 14- day 
period between the time of their biopsy confirming their cancer and their scheduled surgery. Given that  the standard of care time interval between diagnosis/consult and 
curative surgical resection is approximately 4- 6 weeks at the University of Wisconsin, 
treatment with pre- operative cetuximab is not anticipated to delay curative surgical 
resection. No dose reductions of cetuximab are allowed although the rate of infusion of 
the drug can be reduced at the discretion of the investigator  as per the standard  of care 
infusion rate modifications noted in the FDA prescribing information of cetuximab.  
 
Surgical Resection  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
27 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 The surgical  resection is considered  standard of care therapy  for this study  population. 
Patients will undergo definitive standard of care surgery within 4 weeks of the first 
protocol dose of cetuximab.  
Specimens from the tumor resection will be transferred to pathology in culture media or saline per  standard operating  procedures. The biologic  correlate study team will  wait for 
the pathology team to access the specimen in the gross room and then will be given a portion of tissue that will not be required for diagnosis (i.e., remnant). The study team will then process  and embed  that fresh  tissue to an FFPE  block  for downstream  studies. 
Alternatively, the biologic correlate study team will request 20 x 5 µm unstained FFPE slides from the diagnostic tissue after surgical pathology clinical review is complete.  
 
Post- Surgical Assessment  
Patients will be assessed for post -surgical complications (readmission, wound  healing, 
infection) at 1 month +/ - 2 weeks post -surgery. Complications will be categorized as 
related,  probably  related,  possibility  related,  unlikely  related,  or unrelated  to cetuximab.  
 
Post- surgical adjuvant therapy will be delivered based on standard of care therapy as 
per recommendations of the University of Wisconsin Multidisciplinary Head and Neck Oncology Tumor Board. Receiving the two doses of cetuximab in the pre- operative 
setting  will not be grounds  for exclusion of cetuximab use at a later point.  Such  usages 
would include concurrent chemoradiotherapy,
8 palliative combination chemotherapy9 
and/or palliative monotherapy with cetuximab.10 
 
Distant  metastatic  disease and/or  unresectable recurrent  locoregional  disease will be 
managed as per the institutional standard of care.  
 
Expected duration of subject participation  is approximately  13 to 16  months. The time  to 
complete  study  enrollment  is estimated  to be 18 months.  The time to complete  the study 
analysis is estimated to be 30 months (from time of first patient enrolled to the time of last patient completed treatment).  
 
 
4.1 Substudies (if applicable)  
Not applicable.  
 
5 STUDY  ENROLLMENT  AND WITHDRAWAL  
This study  is anticipated to enroll  a target  sample  size of 36 subjects. We estimate 
approximately 100 subjects will be screened to reach the target enrollment.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
28 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 5.1 Subject Inclusion Criteria  
Adult men and women and members of all races and ethnic groups are eligible 
for this trial. Persons with impaired decision- making capacities will not be 
eligible  for enrollment  in this study. Eligibility  criteria  will be assessed via clinical 
labs, review of medical records as well as self -reporting. Subjects will be 
recruited from the University of Wisconsin Hospital and Clinics.  
 
Step 1 registration  will occur when subject  has signed  consent  and consent  has 
been registered (added) to ONCORE.:  
• Age > 18 years  
• Informed consent:  patients  must  be informed  of the investigational  nature of 
the study and must be able to sign a written informed consent.  
• Inclusion  criteria  for research  biopsy  (screen)  
o Patients must have suspected or known clinical presentation of head 
and neck squamous cell carcinoma or a recurrence of head and neck 
squamous  cell carcinoma after initial  therapy.  For newly  suspected head 
and neck cancer, the procedure will obtain tissue for both standard of care biopsy and additional tissue for research.  
o Participants  must have  sufficient  tumor  volume  (approximately  10 cc) to 
accommodate at minimum 2- 3 core samples for the research biopsy. 
This will be approximated based on clinical evidence,  such  as physician 
visualization or palpitation.  
o Patients  are required to consent  to the TSB Biobank  protocol  (2016- 
0934) as part of this study.  
o Surgical  management  must be the chosen  modality  for management  of 
the head and neck squamous cell cancer.  
■ Other  therapeutic  modalities  may follow,  but surgery  must  be the 
choice for first therapy rendered.  
 
For Step 2 enrollment  on this study  an individual  must  meet  all criteria  for Step 
1 and the following criteria:  
• Inclusion criteria for cetuximab treatment:  
o Patients  must  have a biopsy  proven,  squamous  cell carcinoma of the 
head and neck, excluding advanced cutaneous head and neck 
squamous cell carcinoma.  
o ECOG  performance status £ 1 
o Women of childbearing potential (WOCP) must not be pregnant 
(confirmed by a negative urine/serum pregnancy test within 7 days of 
cetuximab treatment).  In addition,  a medically  acceptable  method of birth 
control must be used such as an oral, impl antable, injectable, or 
transdermal hormonal contraceptive, an intrauterine device (IUD), use of 
a double barrier method (condoms, sponge, diaphragm, or vaginal ring  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
29 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 with spermicidal jellies or cream), or total abstinence during the study 
participation and for 6 months after last dose of study drug. Women who 
are postmenopausal  for at least  1 year or surgically  sterile  (bilateral  tubal 
ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP.  
• Men who are not surgically or medically sterile must agree to use an acceptable method of contraception. Male patients with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant  must  agree to use condoms  during the study  and for 6 months 
post study drug. Total abstinence for the same study period is an acceptable alternative.  
• Patients  with other  concomitant  malignancies  are allowed  to participate on 
the clinical trial as long as the surgical resection of the head and neck 
squamous c ell carcinoma is clinically indicated.  
• Patients with metastatic disease are allowed to participate on the clinical trial as long as the surgical  resection of the head and neck  squamous  cell 
carcinoma is clinically indicated.  
• 
5.2 Subject Exclusion Criteria  
An individual  who meets  any of the following  criteria  will be excluded from 
participation in this study:  
• Diagnosis  of nasopharyngeal  carcinoma,  advanced cutaneous  squamous 
cell carcinoma of the head & neck, and salivary gland tumors  
• Other concurrent severe and/or uncontrolled concomitant medical 
conditions  (e.g. active  or uncontrolled infection,  uncontrolled diabetes)  that 
could cause  unacceptable safety  risks or compromise  compliance with the 
protocol  
• Prior chemotherapy, radiotherapy, or major surgery within 8 weeks of study enrollment or those who have not recovered (to grade ≤ 1 or baseline) from clinically  significant  adverse  events  due to agents  administered more than 8 
weeks earlier (alopecia and fatigue excluded). Clinical significance to be determined by the study investigator  
• Prior cetuximab  therapy  is allowed  so long as administered  ³ 8 weeks  ago. 
• History  of allergic  reactions  attributed  to compounds  of chemical  or biologic 
composition similar to those of cetuximab  
• Pregnancy,  breastfeeding,  or expecting  to conceive  or father  children  within 
the projected duration of the trial, starting with the screening visit through 6 
months after the last dose of trial treatment  
• Ongoing  or active  infection,  including  active  tuberculosis  or known infection 
with the human  immunodeficiency  virus  (HIV).  Patients  with chronic,  stable 
infections such as hepatitis C with an undetectable viral load, or HIV  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
30 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 infection  on highly  active  antiretroviral  therapy  with undetectable viral load 
are allowed on the clinical trial.  
• Ongoing treatment  with other  investigational  agent s. 
• Any of the following cardiac conditions:  
o uncontrolled or poorly -controlled  arrhythmia  or uncontrolled cardiac 
insufficiency  
o uncontrolled or poorly -controlled  hypertension (>180 mmHg  systolic  or > 
130 mmHg diastolic)  
• Any of the following conditions:  
o serious  or non-healing wound,  ulcer,  or bone fracture  
o history  of abdominal  fistula,  gastrointestinal  perforation,  or intra- 
abdominal abscess within 28 days of study enrollment  
o history  of cerebrovascular  accident  (CVA)  or transient  ischemic  attack 
within 12 months prior to study enrollment  
o history of myocardial infarction, ventricular arrhythmia, stable/unstable 
angina,  symptomatic  congestive  heart  failure,  coronary/peripheral  artery 
bypass graft or stenting or other significant cardiac disease within 6 months prior to study enrollment  
o history  of arterial  or venous  thrombosis/thromboembolic  event,  including 
pulmonary embolism within 6 months of study enrollment  
o any condition requiring the use of immunosuppression, excluding 
rheumatologic  conditions  treated  with stable  doses  of corticosteroids  
o Use of herbal  supplements  (St. John’s  Wort,  gingko  biloba,  etc.) within 
one week of cetuximab treatment  
 
For patients  who do not meet  eligibility  criteria  for Step 2 of the study,  the tissue 
from the research biopsy will be released to the TSB Biobank or back to 
surgical pathology if needed for a clinical diagnosis.  
 
5.3 Strategies for Recruitment and Retention  
The most common method that will be used to recruit subjects is through pre-  
screening of medical records for patients of a study physician. Members of the 
study team will preview the schedules of the study physicians to determine the gross  eligibility  of upcoming patients.  When  a patient  may meet  gross  eligibility, 
study team members will notify the physician. At the patient’s next clinic visit, the physician may then include a discussion about study participation w ith the 
patient.  
 
5.3.1  Subject Remuneration 
Subjects  are eligible  to receive up to $200 for  participating in this study  to offset  the 
barriers of the extra research procedures and visits.  Participants will be 
provided remuneration in the amount of $100 after the research biopsy, and  
$50 after each  CTX administration.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
31 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
  
 
 
 
5.4 Treatment Assignment Procedures  
Not applicable.  This is a single  arm Window  of Opportunity  study.  
 
5.5 Subject Withdrawal  
Subjects  may withdraw  voluntarily  from the study  or the investigator  may 
terminate a subject's participation.  
5.5.1  Reasons  for Withdrawal  
In addition  to discontinuation from therapy  related  to toxicities  as outlined in the 
Halting Rules of Section 9.5, a subject will also be discontinued from protocol 
therapy and followed up per protocol under the following circumstances:  
• Documented disease  progression  
• The treating physician  thinks  a change  of therapy  would  be in the best 
interest of the subject.  
• The subject  requests  to discontinue  protocol  therapy,  whether  due to 
unacceptable toxicity or for other reasons.  
o If a subject decides to prematurely discontinue protocol therapy 
(“refuses treatment”), the subject should be ask ed if he or she may still 
be contacted for further  scheduled study  assessments.  The outcome of 
that discussion should be documented in both the medical records and in the electronic case report form (eCRF).  
• A female subject  becomes  pregnant.  
• The subject  meets an exclusion  criterion  (either  newly  developed or not 
previously recognized) that precludes further study participation.  
 
Subjects  will be removed from protocol  therapy  and the site investigator  notified 
when any of the criteria listed above apply. The reason for discontinuation of 
protocol therapy will be documented on the eCRF.  
 
5.5.2  Handling of Subject  Withdrawals  or Subject  Discontinuation of Study  
Intervention  
If a subject decides to withdraw from the study (and not just from protocol 
therapy)  all efforts  should  be made  to complete and report  study  assessments 
as thoroughly as possible. The study team should contact the subject or a responsible relative by telephone to establish as completely as possible the reason for the study withdrawal. A complete final evaluation at the time of the subject’s stu dy withdrawal should be made with an explanation of why the  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
32 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 subject  is withdrawing  from the study.  If the reason  for removal  of a subject 
from the study is an adverse event, it will be recorded on the eCRF.  
 
If a subject is unevaluable for safety and efficacy endpoints (i.e., lacks 
molecular/correlative studies, and creation of PDXs, subject has not received both cetuximab  doses  in their entirety  and/or  has not had surgical  resection  of 
the tumor), then the subject will be replaced at the disc retion of the principal 
investigator.  
 
5.6 Premature  Termination  or Suspension of Study  
This study may be suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the reason for study suspension or terminat ion, will be provided by the suspending or terminating 
party to NIDCR and regulatory authorities. If the study is prematurely terminated  or suspended,  the principal  investigator  will promptly  inform  the IRB 
and will provide the reason(s) for the termination or suspension.  
 
Circumstances  that may warrant  termination  include,  but are not limited  to: 
 
• Determination of unexpected,  significant,  or unacceptable risk to subjects 
• Insufficient adherence to protocol  requirements  
• Data  that are not sufficiently  complete and/or  evaluable 
• Determination  of futility  
 
6 STUDY INTERVENTION  
 
6.1 Study Product Description  
Cetuximab (Erbitux®) is a Monoclonal  Antibody/Epidermal  Growth  Factor 
Receptor (EGFR) Inhibitor. It is indicated for the treatment of:  
 
• locally  or regionally  advanced squamous  cell carcinoma of the head and 
neck (SCCHN) in combination with radiation therapy;  
• recurrent  locoregional  disease  or metastatic  squamous  cell carcinoma  of the 
head and neck in combination with platinum -based therapy with 5- FU; and  
• recurrent  or metastatic  squamous  cell carcinoma  of the head  and neck 
progressing after platinum -based therapy.  
See Package Insert for further information.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
33 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 6.1.1  Acquisition  
Commercial  Cetuximab will be utilized  in this study.  Cetuximab will be prepared 
and administered per UWHC pharmacy and hospital guidelines.  
 
See Package Insert for further information.  
 
6.1.2  Formulation, Packaging, and Labeling 
Erbitux  is a sterile,  clear,  colorless  liquid  of pH 7.0 to 7.4, which  may contain a 
small amount of easi ly visible, white, amorphous cetuximab particulates.  
Erbitux  is supplied  at a concentration of 2 mg/mL  in either  100 mg (50 mL) or 
200 mg (100 mL), single -use vials.  Cetuximab  is formulated  in a solution  with 
no preservatives, which contains 8.48 mg/mL sodium chloride, 1.88 mg/mL 
sodium phosphate dibasic heptahydrate, 0.41 mg/mL sodium phosphate monobasic monohydrate, and Water for Injection, USP.  
 
Cetuximab is supplied at a concentration of 2 mg/mL as a 1 00 mg/50 mL, 
single -use vial or as a 200 mg/100  mL, single -use vial as a sterile,  injectable 
liquid containing no preservatives.  
 
Cetuximab can be supplied to two dosage forms:  
• A 100 mg/50  mL, single -use vial, individually  packaged in a carton  (NDC 
66733- 948-23) 
• A 200 mg/100  mL, single -use vial, individually  packaged in a carton  (NDC 
66733- 958-23) 
 
6.1.3  Product  Storage  and Stability  
Product  vials will be stored under  refrigeration at 2º C to 8º C (36º F to 46º F). 
Product will not be frozen. Increased particulate formation may occur at 
temperatures at or below 0º C. This product contains no preservatives.  
Preparations of Erbitux in infusion containers are chemically and physically 
stable for up to 12 hours at 2º  C to 8º C (36º F to 46º F) and up to 8 hours at 
controlled room temperature (20º C to 25º C; 68º F to 77º F). Any remaining solution will be discarded in the infusion container after 8 hours at controlled room  temperature or after 12 hours  at 2º to 8º C. Any unused  portion  of the vial 
will be discarded.  
 
6.2 Dosage, Preparation and Administration of Study Product  
 
Cetuximab  Preparation  
Cetuximab will not be administered  as an intravenous  push  or bolus.  It will only 
be administered via infusion pump or syringe pump. The infusion rate will not exceed 10 mg/min.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
34 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Cetuximab will be administered through a low protein  binding 0.22-micrometer 
in-line filter.  
 
Parenteral drug products will be inspected visually for particulate matter and 
discoloration prior to administration, whenever solution and container permit. The solution  should  be clear  and colorless  and may contain  a small  amount  of 
easily  visible,  white,  amorphous,  cetuximab particulates.  The solution is not to 
be shaken or diluted.  
 
Cetuximab  Administration Guidelines  
Treatment with cetuximab will occur during the period between initial diagnosis and surgical resection. The standard of care (SOC) commonly utilizes approximately  4 weeks  after diagnosis  for preoperative scheduling and medical 
optimization.  As such, this clinical  trial does  not delay  standard of  care curative 
treatment for head and neck cancer.  
 
Prior to administration  of cetuximab,  subjects  will be premedicated with 
diphenhydramine and acetaminophen as described in Section 6.6.  
 
For Dose  #1, subjects will be treated  with cetuximab  400 mg/m
2 via intravenous 
infusion  over 2 hours  (maximum infusion rate 10 mg/min)  as per the standard of 
care loading regimen for cetuximab monotherapy.1 
 
For Dose  #2, subjects  will be treated  with cetuximab 250 mg/m2 via intravenous 
infusion over 1 hour (maximum infusion rate 10 mg/min) as per the standard of care dosing regimen for cetuximab monotherapy.
1 
See section  6.6 for concomitant  medication  as cetuximab pretreatment. 
Cetuximab Administration Monitoring  
• Vitals signs will be monitored every 15 minutes for the first hour, and then every  30 minutes  until cetuximab  infusion is complete  for the first infusion  as 
per the University of Wisconsin Hospital and Clinic guidelines. The nurse should remain with the patient for the first 15 minutes of drug administration for the first and second dose of cetuximab administration as per the University of Wisconsin Hospital and Clinics guidelines  
• Hypersensitivity  reaction to cetuximab can occur.  For first and second dose, 
patient should be treated in a location to optimize emergency care.  
• For the first dose of cetuximab,  the subject must  remain in the treatment 
area for 60 minutes  following  the completion of the cetuximab as per the 
University of Wisconsin Hospital and Clinics guidelines.  
 
Supportive Care  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
35 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Optimal  patient  care is to be given to all patients.  
 
6.2.1  Potential  adverse events  and precautions  
 
Infusion  Reactions  
Serious  infusion  reactions  can occur  during cetuximab  administration.  Serious 
infusion reactions include rapid onset of airway obstruction (bronchospasm, 
stridor, hoarseness), hypotension, shock, loss of consciousness, myocardial infarction, and/or cardiac arrest. Severe (NCI CTC Grades 3 and 4) infusion reactions occurred in 2 –5% of patients in prior clinical studies with a fatal 
outcome in 1 patient [Cetuximab FDA prescribing information].
8,10,62,63 
 
Approximately  90% of severe infusion reactions  occurred with the first infusion 
despite premedication with antihistamines. Thus, patients must be monitored for at least 1 hour following cetuximab infusions in a setting with resuscitation equipment  and other  agents  necessary  to treat anaphylaxis  (e.g.,  epinephrine, 
corticoster oids, intravenous antihistamines, bronchodilators, and oxygen). For 
any subjects who experience an infusion reaction, longer monitoring may be necessary and is appropriate to confirm resolution of the event.  
 
In the event  of an infusion  reaction,  
• For NCI CTC grade 1, grade 2, and non- serious grade 3 infusion 
reaction,  cetuximab will be temporarily  held with administration  of 
emergency medications as appropriate by the treating physician. Upon resolution of the infusion reaction, subjects may be rechallenged  with cetuximab at a reduced infusion rate.  
• For serious  grade 3 and all grade 4 infusion reactions,  cetuximab  will 
be permanently discontinued.  
• All subjects  should receive appropriate medical  intervention as 
appropriate by the treating physician  
• Emergency  medications  to be available in the event  of an infusion 
reaction include:  
■ Diphenhydramine 25-50 mg IV 
■ Dexamethasone 4-10 mg IV 
■ Albuterol  nebulization solution  2.5 mg/3ml  
 
Cardiopulmonary  Arrest  
Cardiopulmonary arrest and/or sudden death occurred in 4 (2%) of 208 patients treated with radiation therapy and cetuximab as compared to none of 212 patients treated with radiation therapy alone.
8 Three patients with prior 
history of coronary artery disease died at home, with myocardial infarction as the presumed cause of death. One of these patients had arrhythmia and one had congestive  heart  failure.  Death  occurred 27, 32, and 43 days  after the last 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
36 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 dose of cetuximab.  One patient  with no prior history  of coronary  artery  disease 
died one day after the last dose of cetuximab. In Study 2, fatal cardiac 
disorders and/or sudden death occurred in 7 (3%) of 219 patients treated with EU-approved cetuximab and platinum -based therapy with 5- FU as comp ared 
to 4 (2%) of 215 patients treated with chemotherapy alone.
9 Five of these 7 
patients in the chemotherapy plus cetuximab arm received concomitant cisplatin and 2 patients received concomitant carboplatin. All 4 patients in the chemotherapy -alone arm received cisplatin. Cardiopulmonary arrest and/or 
sudden death has been observed in a small percentage of patients during the 
trials that have led to approval of cetuximab, resulting in the issuance of an 
FDA black box warning.
1 
 
During  cetuximab  treatment  and after completion of cetuximab  treatment, 
subjects  will have close  monitoring of serum  electrolytes,  including  serum 
magnesium, potassium, and calcium.  
 
Development  of cardiopulmonary  arrest  will result  in permanent 
discontinuation of cetuximab.  
 
Pulmonary  Toxicity  
Interstitial lung disease (ILD), including 1 fatality, occurred in 4 of 1570 
(<0.5%)  patients  receiving cetuximab  in colorectal  cancer  and head and neck 
cancer.8,10,63  
• Subjects  who develop acute  onset  pulmonary  symptoms  should have the 
cetuximab withheld and be evaluated by the treating physician.  
• Subjects  who have  confirmed interstitial lung disease  after treatment  with 
cetuximab will be permanently discontinued from cetuximab treatment.  
 
Dermatologic  Toxicity  
Dermatologic toxicities, including acneiform rash, skin drying and fissuring, 
paronychial  inflammation,  infectious  sequelae  (for example,  S. aureus  sepsis, 
abscess formation, cellulitis, blepharitis, conjunctivitis, keratitis/ulcerative 
keratitis  with decreased visual  acuity,  cheilitis),  and hypertrichosis  occurred  in 
patients receiving cetuximab therapy. Acneiform rash occurred in 76 –88% of 
1373 patients  receiv ing cetuximab.8,10,62,63 Severe acneiform  rash occurred  in 
1–17% of patients. Acneiform rash usually developed within the first two 
weeks of therapy and resolved in a majority of the patients after cessation of treatment, although in nearly half, the event continued beyond 28 days.  
 
• Study  subjects  will be monit ored for dermatologic  toxicities  and infectious 
sequelae.  
• Subjects  will be instructed to limit sun exposure during cetuximab treatment  
• Severe  (NCI CTC Grade 3 or 4) acneiform  rash will result  in discontinuation 
of cetuximab therapy.1 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
37 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 • Intolera ble grade 2 rash,  despite maximum  supportive care,  will result  in 
discontinuation.  
• NCI CTC Grade 1 or 2 rash is to be treated with one or more of the 
following medications at the treating physician’s discretion, based upon 
supportive care evidence.64 Potential medications that can be used for the 
treatment  of cetuximab -related rash may include,  but are not limited  to, the 
following:  
■ Hydrocortisone  1 to 2.5%  lotion  
■ Doxycycline  100 mg bid 
■ Clindamycin  1% lotion  
 
Hypomagnesemia  and Electrolyte  Abnormalities  
• Periodic  monitoring for hypomagnesemia,  hypocalcemia,  and hypokalemia 
will be performed during and after completion of cetuximab. All 
abnormalities will be noted in the patient’s medical record. The treating 
clinician will determine if the abnormality is clinically significant. Repletion of electrolyte deficits w ill be performed as per discretion of the treating 
physician.  
 
Assessment  of Research  Biopsy  Site 
• Assessment  of the research biopsy  site will be monitored by treating 
physician until resolution.  
 
6.3 Modification  of Study  Product  Administration for a Subject 
Dose Delays/Dose Modifications  
• No dose modifications  will be planned.  Please refer to section 6.2.1  
(subsection,  Infusion Reactions)  for more  information regarding infusion rate 
decreases in the setting of infusion reaction.  
• Dose delays secondary t o intolerance (such as infusion reactions) are 
permitted.  Subjects  can be rechallenged with cetuximab within  3 days  but 
will otherwise be discontinued from the study.  
• Expected adverse events  that would  delay  cetuximab  infusion:  
- Grade 3 or higher nausea, vomiting, diarrhea, stomatitis, or rash 
uncontrolled despite maximal  medical  management  due to a toxicity  that 
is considered at least PROBABLY related to study treatment  
- Any other  Grade  3 or higher  non-hematologic  toxicity,  except  grade  3 
fatigue lasting >7 days, due to a toxicity that is considered at least PROBABLY related to study treatment  
- Grade  3 or 4 electrolyte abnormalities  that are corrected  within  48 hours 
will not be considered a serious adverse event.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
38 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 6.4 Acco untability Procedures for the Study Product  
Cetuximab will be obtained and purchased as a commercial supply. The 
investigator or an approved representative (e.g. pharmacist) must maintain accurate records  of dates  and quantities  of CTX dispensed under  this study, 
and to whom study drug is dispensed.  
Cetuximab should  be stored  in a secure area according to local regulations. 
Cetuximab must be dispensed only from official study sites by authorized personnel according to local regulations.  
 
Drug Destruction  
Opened vials must  be disposed of at the site as chemotherapy  or biohazardous 
waste, provided documented procedures for destruction are in place.  
 
 
6.5 Assessment  of Subject  Compliance  with Study  Product  Administration  
Not applicable.  
 
6.6 Concomitant Medications/Treatments 
Prior to cetuximab  (CTX) administration,  participants  will be premedicated  with 
two medications, taking place 30- 60 minutes prior to treatment:  
• an H1 antagonist (50 mg of diphenhydramine) intravenously administered over 1 minute,  taking place 30–60 minutes  prior to the first 
dose; premedication will be administered for the subsequent cetuximab dose based upon clinical judgment and presence/severity of prior infusion reactions.
1 
• Acetaminophen (650 mg orally)  will be administered  30-60 minutes  prior 
to chemotherapy as per University of Wisconsin Hospital and Clinics 
guidelines.  
 
 
 
 
7 STUDY SCHEDULE  
See table in Appendix  A. When  calculating days  of tests  and measurements,  the day a 
test or measurement is done is considered Day 0. Therefore, if a test were done on a 
Monday, the Monday one week later would be considered Day 7.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
39 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 COVID- 19 testing: Literature  reports  suggest  that SARS -CoV -2 can be detected  in the saliva  of 
patients known to be infected with the virus. Therefore COVID -19 testing may be required per 
UWHC recommendations for aerosolizing procedures (research biopsy for correlative study).  
 
 
7.1 Screening / Baseline  Visit  (Day  -21 to 1) 
Study  Visit 1 and  2 
• Informed consent/HIPAA authorization obtained prior to any research 
procedures.  Subjects  will also be required to sign biobanking consent  for 
banking of residual study samples. (research- related)  
• Demographics  (recorded  for the study  from medical  records  maintained as 
part of standard clinical care)  
• Medical  history  including  prior therapies  and pathology  (recorded  for the 
study from medical records maintained as  part of standard clinical care)  
• Concomitant  medications  (recorded  for the study  from medical  records 
maintained as part of standard clinical care)  
• Physical  exam,  height  (screening only),  weight  (recorded for the study  from 
medical records maintained as part of standard clinical care)  
• Vital signs  (blood pressure,  heart  rate, temperature)  (recorded for the study 
from medical records maintained as part of standard clinical care)  
• ECOG  performance  status  (recorded  for the study  from medical  records 
maintained as part of standard clinical care)  
• CBC with differential  (recorded for the study  from medical  records 
maintained as part of standard clinical care)  
• Blood chemistries (sodium, potassium, chloride, bicarbonate, BUN creatinine,  glucose,  AST,  ALT,  Alk Phos,  T. bili, calcium,  magnesium,  
• T. protein  and albumin (recorded for the study  from medical records 
maintained as part of standard clinical care)  
• Within 7 days prior to initiation of cetuximab: Urine pregnancy test for women of childbearing potential (WOCP). If the urine test is positive or cannot  be confirmed as negative,  a serum  pregnancy  test will be required. 
(standard clinical care for CTX administration)  
• Adverse  event  evaluation (standard clinical care for CTX administration)  
• Research biopsy  for biological  correlative studies  
• Research blood draw  for analysis  of circulating  tumor  cells/biomarkers  
• Measurement  of tumor  size via clinical assessement  (research -related)  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
40 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 7.2 Intermediate Visits  
Study  Visit  3, Cetuximab  Dose  1 
• Vital signs  (blood pressure,  heart  rate, temperature)  (recorded for the study 
from medical records maintained as part of standard clinical care for CTX 
administration)  
• Weight  (recorded  for the study  from medical  records  maintained as part of 
standard clinical care for CTX administration) Only required if 
screening/baseline vis it > 7 days prior to treatment.  
• CBC with differential (recorded for the study from medical records 
maintained as part of standard clinical care for CTX administration)  Only 
required if screening labs > 7 days prior to treatment.  
• Blood chemistries (sodium, potassium, chloride, bicarbonate, BUN 
creatinine, glucose, AST, ALT, Alk Phos, T. bili, calcium, magnesium, T. protein and albumin) (recorded for the study from medical records maintained as part of standard clinical care for CTX administration).  Only 
required if screening labs > 7 days prior to treatment.  
• Adverse  event  evaluation (standard clinical care for CTX administration)  
• Administration  of cetuximab (research- related)  
 
 
Study  Visit  4, Cetuximab  Dose  2 (7 days  +/- 3 days  from  Study  Visit  3) 
• Vital signs (blood pressure only) (recorded for the study from medical records  maintained as part of standard  clinical care for CTX administration)  
• Blood Chemistry: Potassium, calcium and magnesium (recorded for the study  from medical  records  maintained as part of standard clinical care for 
CTX administration)  
• Adverse  event  evaluation (standard clinical care for CTX administration)  
• Administration  of cetuximab (research- related)  
 
 
Study  Visit  5, Safety  Evaluation  (within  7 days prior  to surgery)  
• Concomitant  medications  (recorded  for the study  from medical  records 
maintained as part of standard clinical care for CTX administration)  
• Physical  exam  (recorded  for the study  from medical  records  maintained as 
part of standard clinical care for CTX administration)  
• Vital signs  (blood pressure,  heart  rate, temperature)  (recorded for the study 
from medical records maintained as part of standard clinical care for CTX 
administration)  
• Weight  (recorded  for the study  from medical  records  maintained as part of 
standard clinical care for CTX administration)  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
41 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 • ECOG  performance status  (recorded  for the study  from medical  records 
maintained as part of standard clinical care for CTX administration)  
• CBC with differential (recorded for the study from medical records 
maintained as part of standard clinical care for CTX administration)  
• Blood chemistries (chloride, bicarbonate, BUN creatinine, glucose, AST, ALT, Alk Phos, T. bili, calcium, magnesium, T. protein and albumin) (recorded for the study  from medic al records  maintained as part of standard 
clinical care for CTX administration)  
• Adverse  event  evaluation (standard clinical care for CTX administration)  
• Measurement  of tumor  size via clinical  assessment  (research -related)  
 
 
SOC Surgery  
• Blood draw for pre- surgical measurement of circulating tumor 
cells/biomarkers  in serum  should be done within  1 day prior to surgery 
(Research procedure)  
• During  surgery,  a portion of the resected tumor  which  pathology  will not 
need for diagnosis (remnant tissue) will be obtained for study analysis  
 
 
SOC  Follow  Up Visit  1, 1 month post -surgery  (+/- 2 wk) 
• Blood draw  for post-surgical  measurement  of circulating  tumor 
cells/biomarkers in serum (Research procedure)  
• Concomitant  medications  (recorded  for the study  from medical  records 
maintained as part of standard clinical care)  
• Physical  exam  (recorded  for the study  from medical  records  maintained as 
part of standard clinical care)  
• Vital signs  (blood pressure,  heart  rate, temperature)  (recorded for the study 
from medical records maintained as part of standard clinical care)  
• Weight  (recorded  for the study  from medical  records  maintained as part of 
standard clinical care)  
• ECOG  performance status  (recorded  for the study  from medical  records 
maintained as part of standard clinical care)  
• Serious  adverse event  evaluation (pertains  to both research- related (section 
9.1) AND standard clinical care)  
 
SOC  Follow  Up Visit  2, 3 months  post -definitive  treatment*  (+/- 4 wk) 
• Physical  exam  (recorded  for the study  from medical  records  maintained as 
part of standard clinical care)  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
42 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 • Vital signs  (blood pressure,  heart  rate, temperature)  (recorded for the study 
from medical records maintained as part of standard clinical care)  
• ECOG  performance status  (recorded  for the study  from medical  records 
maintained as part of standard clinical care)  
• Neck  Imaging (findings  recorded for the study  from medical  records 
maintained as part of standard clinical care)  
• Blood  draw  for post-surgical  measurement  of circulating  tumor 
cells/biomarkers in serum ( research -related procedure)  
7.3 Final Study Visit  
SOC  Follow  Up Visit  3, 12 months  post -definitive  treatment*  (+/- 4 wk) 
• Physical  exam  (recorded  for the study  from medical  records  maintained as 
part of standard clinical care)  
• Vital signs  (blood pressure,  heart  rate, temperature)  (recorded for the study 
from medical records maintained as part of standard clinical care)  
• Weight  (recorded  for the study  from medical  records  maintained as part of 
standard clinical care)  
• ECOG  performance status  (recorded  for the study  from medical  records 
maintained as part of standard clinical care)  
• Neck  Imaging (findings  recorded for the study  from medical  records 
maintained as part of standard clinical care)  
• Blood  draw  for post-surgical  measurement  of circulat ing tumor 
cells/biomarkers in serum (research- related procedure)  
 
* Definitive  therapy  is defined  as surgery  alone,  surgery  + XRT or Surgery  + 
chemoXRT  
 
 
7.4 Withdrawal Visit 
If a subject decides to withdraw from the study (and not just from protocol 
therapy)  all efforts  should  be made  to complete and report  study  assessments 
as thoroughly  as possible.  The treating  investigator  should contact  the subject 
or a responsible relati ve by telephone to establish as completely as possible 
the reason for the study withdrawal. A complete final evaluation at the time of the subject’s study withdrawal  should be made with  an explanation of why the 
subject is withdrawing from the study. If the reason for removal of a subject from the study is an adverse event, it will be recorded on the eCRF.  
 
7.5 Unscheduled Visit 
If a study subject should need an unscheduled visit, the treating physician 
should document  the reason for the unscheduled visit (preferably  in a clinic  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
43 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 note in the patient’s chart). A complete description of the subject’s symptoms 
and appropriate physical examination should be performed. In addition, the treating physician should document any recommendations and treatment plan for the subject  at the time of the clinic  visit. This information will be recorded on 
the eCRF.  
 
8 STUDY PROCEDURES /EVALUATIONS  
 
8.1 Study Procedures/Evaluations 
Criteria  for Disease  Assessment  
Assessment of Clinical  Benefit  Rate 
Response assessment of cetuximab on clinical lesions will be determined by quantitative measurement performed by the treating physician pre- treatment 
and at the time of surgery. Response Evaluation Criteria in Solid Tumors (RECIST)  1.1 Committee
65 criteria  will be used  to define clinical response prior 
to surgery.  
 
Assessment of Disease  Recurrence 
Participants  will be evaluated for evidence of recurrence  on 2 occasions: 3 and 
12 months post -definitive treatment (recorded for the study from medical 
records maintained as part of standard clinical car e). 
 
Given  that all known disease will be surgically  resected at the time of surgery, 
the only measure of relevance for this study will be recurrence of disease.  
Recurrence will be evaluated in this study  using the new international  criteria 
proposed by the RECIST 1.1 Committee.65 Note: Lesions are either 
measurable or non- measurable using the criteria provided below.  
 
Measurable Disease  
At baseline,  tumor  lesions/lymph  nodes  will be categorized measurable or non- 
measurable as follows (per RECIST 1.1).65 
 
Tumor  lesions:  
Measurable lesions  are defined as those that can be accurately  measured  in at 
least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of:  
o 10 mm by CT scan (CT  scan slice thickness no  greater  than 5 mm) 
o 10 mm measurement by clinical exam (lesions which cannot be 
accurately  measured  or are <10mm  should be recorded as non- 
measurable)  
o 20 mm by chest X -ray.as >20 mm with conventional techniques (CT, 
MRI,  x-ray) or as >10 mm with spiral  CT scan. All tumor  measurements  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
44 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 must be recorded in millimeters  (or decimal  fractions  of centimeters).  To 
be considered pathologically enlarged and measurable, a lymph node 
must be ≥ 15 mm in short axis when assessed by CT scan.  
 
Malignant lymph nodes:  
To be considered pathologically  enlarged and measurable,  a lymph  node must 
be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow -up, only 
the short axis will be measured and followed. The measurements will be recorded for the study from medical records maintained as part of  standard 
clinical care.  
 
Non-measurable disease  
All other  lesions  (or sites of disease),  including small lesions  (longest  diameter  
<10 mm or pathological  lymph  nodes  with ≥ 10 to <15 mm short  axis)  as well as 
truly non- measurable lesions. Lesions considered truly non- measurable 
include: leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly  identified by physical exam that is 
not measurable by reproducible imaging techniques.  
 
8.2 Laboratory Procedures/Evaluations 
8.2.1  Clinical Laboratory Evaluations  
All clinical labs and evaluations  done in this study  are performed as standard 
medical care.  
 
8.2.2  Special  Assays  or Procedures  
Research  Biopsy  
Collection  of specimen:  In order  to participate in this study, the tumor  must  be 
large enough to allow for the correlative study endpoints to be achieved. The minimum amount of tissue to achieve this is 2 -3 core samples from the 
research biopsy with a strong preference for a cut -forceps biopsy (minimum 
recommended size: 2 x 2 x 2mm) . 
 
Remnant  Tumor  Tissue  
Collection of surgical specimen:  All specimens will go directly to the UWHC 
pathology department for diagnosis and processing. The biologic correlate study  team  will wait for the pathology  team  to access the specimen in the gross 
room and then will be given a portion of tissue that will not be required for 
diagnosis (i.e., remnant).  
 
Circulating Tumor Cells/Biomarkers  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
45 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Collection of specimen:  We will collect blood for circulating tumor cell/or other 
biomarker  identification  at five timepoints:  baseline,  prior to surgical  resection, 
one month post surgery, 3 and 12 months post definitive treatment.  
Approximately  10mL  of blood will be collected  in heparinized  vaccutainers 
(green top) at each time point.  
 
Establis hment of Patient -Derived Xenografts  
Collection  of specimen:  The research biopsy  will also be used to establish 
patient -derived xenografts.  
 
Determination  of putative  biomarkers  of CTX sensitivity  
Collection  of specimen : the research biopsy  will also be used for correlative 
analysis of putative biomarkers of CTX sensitivity.  
 
8.2.3  Specimen  Preparation,  Handling,  and Storage  
Research  Biopsy  
Processing of specimen:  The tissue obtained for research biopsy  will be placed 
in culture media or saline, stored at room temperature and provided to the 
biologic correlate study team within 3 hours post -surgery. The samples will be 
identified with the research study number and “research biopsy”. The label will be stripped of all patient identifiers, such as MR number or dates. If squamous cell carcinoma is NOT confirmed, the tissue from the research biopsy will be relinquished to the TSB Biobank or surgical pathology based on clinical need.  
 
Approximately 1/3 of the research biopsy will be formalin fixed and paraffin embedded . The remaining tissue will be used  directly  in mice  to establish  the 
first panel of PDX from patients with known sensitivity or resistance to cetuximab.  
 
Tumor  Tissue  
Processing of specimen:  The study team will process and embed the fresh 
tissue obtained from the pathology department to an FFPE block for downstream  studies. Alternatively,  the biologic  correlate study  team  will request 
20 x 5 µm unstained FFPE slides from the diagnostic tissue  after surgical 
pathology clinical review is complete. The specimens will be labeled with the research study number, “surgical resection,” and section number, if applicable. The label will be stripped of all patient identifiers, such as the medical record number or dates.  
 
Research Tissue samples  and PDXs  within  the context of this protocol  will be 
maintained under the supervision of Dr. Randy Kimple located at:  
University  of Wisconsin 
3107 WIMR  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
46 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 1111 Highland Avenue  
Madison WI 53705  
 
Circulating  Tumor  Cells/Biomarkers  
Processing of specimen:  The samples will be picked up by a member of the 
biologic correlative study team and transported to Dr. Hong’s lab. Upon arrival 
at the lab,  PHI patient identifiers will be stripped from the sample and 
relabeled. The samples will be labeled with the subject’s study ID number and coded time point (1- baseline, 2- pre-surgical resection, 3- one month post 
surgery, 4- three months post definitive- treatment, 5 - twelve months post 
definitive treatment). Processing and storage of the circulating tumor cell samples  within  the context of this protocol  will occur under  the supervison of Dr. 
Seungpyo Hong’s lab located at:  
 
Pharmaceutical Sciences Division 
University  of Wisconsin School  of Pharmacy 
7234 Renneb ohm Hall  
777 Highland  Avenue  
Madison WI 53705  
 
Determination  of putative  biomarkers  of CTX sensitivity  
The biologic correlate study team will formalin fix and paraffin embed (FFPE) 
approximately one third of the research biopsy tissue to be used to assess putative biomarkers of CTX sensitivity (e.g. total and phosphorylated AXL, EGFR  and HER3  expression usi ng immunohistochemistry  assays). The FFPE 
research and surgical specimens will be used to establish the change in Ki67 (ΔKi67).  
 
Correlations between the change in Ki67 index (ΔKi67) and AXL expression and HER3 expression in the research biopsy will be performed. Further correlation between  other  biomarkers  and AXL expression will be performed.  
 
Determination  of circulating  tumor  cells  
We hypothesize that changes in circulating tumor cells detected using the described head and neck cancer optimized capture approach (section 2) will correlate with response as determined by change in Ki67. Circulating tumor cells will be quantified at each time point.  In addition,  we plan to utilize  captured 
circulating tumor cells to establish the first reported circulating tumor cell - 
derived head and neck  cancer  patient  derived  xenografts  and to compare  these 
PDXs to those established using standard techniques.  
 
8.2.4  Specimen  Shipment  
Not applicable.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
47 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 9 ASSESSMENT OF SAFETY  
 
9.1 Specification  of Safety Parameters  
Adverse event  data collection and reporting,  which  are required as part of every 
clinical trial, are done to ensure the safety of patients enrolled in the studies as 
well as those who will enroll in future studies using similar agents. Adverse events are reported in a routine manner at scheduled times during a trial.  
Additionally , certain adverse events must be reported in an expedited manner 
to allow for optimal monitoring of patient safety and care. The first step is to identify the event using the Common Terminology Criteria for Adverse Events (CTCAE).  The CTCAE  document  provides  descriptive terminology  for adverse 
event reporting. A grading (severity) scale is provided for each adverse event term.  
 
Adverse events, Serious adverse events and unanticipated problems will be recorded  on the study  eCRF’s  and reported  per section 9.4. Certain  toxicities 
are known and can be expected.  
 
Cetuximab:  
Common: Change in nails, rash, itching, dry skin, acne, dehydration,  
weight loss, loss of appetite, sores in mouth which may cause difficulty swallowing, constipation, diarrhea, vomiting, nausea, difficulty sleeping, headache,  tiredness,  pain,  fever,  infection,  especially  when  white  blood cell 
count is low, cough, shortness of breath, hypomagnesemia, hypokalemia and hypocalcemia  
 
Occasional: Allergic  reaction which  may cause rash,  low blood  pressure, 
wheezing, shortness of breath, swelling of the face or throat, confusion, depression, worry, fainting, severe blood infection, blood clot which may cause swelling, pain, shortness of breath  
 
Rare:  Scarring  of the lungs,  kidney  damage  which  may require  dialysis, 
cardiac arrest  
 
Additional risks from study procedures  
Biopsy  
Possible  risks from a tissue biopsy  include  bleeding and infection.  There 
can also be some degree of pain associated with the biopsy.  
 
Blood draw  
Possible  risks include:  pain,  bleeding  and/or  bruising,  feeling faint,  infection 
with redness, irritation, and, more rarely, a blood clot in the vein at the site where the blood is drawn.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
48 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 In addition to physical risks there is also the risk of “breach of 
confidentiality”.  If this occurs,  it will be reported  as an unanticipated 
problem.  
 
9.1.1  Unanticipated  Problems  
The Office  for Human Research Protections  (OHRP)  considers  unanticipated 
problems involving risks to subjects or others to include, in general, any 
incident, experience, or outcome that meets all of the following criteria:  
• unexpected in terms of nature, severity, or frequency given (a) the 
research procedures that  are described in the protocol -related 
documents, such as the IRB -approved research protocol and informed 
consent  document;  and (b) the characteristics  of the subject  population 
being studied;  
• related or possibly  related to participation in the research (“possibly 
related” means there is a reasonable possibility that the incident, 
experience, or outcome may have been caused by the procedures involved in the research); and  
• suggests  that the research  places  subjects or others  at a greater  risk of 
harm (including physical,  psychological,  economic,  or social  harm)  than 
was previously known or recognized.  
 
 
9.1.2  Adverse  Events  
An adverse event is any untoward or unfavorable medical occurrence in a 
human subject, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s  participation in the research,  whether  or not considered  related to 
the subject’s participation in the research.  
 
9.1.3  Serious  Adverse Events  
A serious  adverse  event  (SAE)  is one that meets  one or more  of the following 
criteria:  
• Results  in death  
• Is life-threatening (places  the subject  at immediate  risk of death  from 
the event as it occurred)  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
49 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 • Results  in inpatient  hospitalization or prolongation of existing 
hospitalization 
• Results  in a persistent  or significant  disability  or incapacity  
• Results in a congenital  anomaly  or birth defect  
• An important medical event that may not result in death, be life 
threatening,  or require  hospitalization  may be considered an SAE when, 
based upon appropriate medical judgment, the event may jeopardize 
the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
 
9.2 Time  Period and Frequency  for Event  Assessment  and Follow -Up 
Unanticipated problems will be recorded in the data collection system throughout 
the duration of the study.  
 
All AE’s will be recorded from the time of informed consent until 28 days past last 
dose of study drug or day of surgery, whichever is first. SAE’s wi ll be recorded 
from the time of informed consent  through 28 days  past last dose of study  drug or 
28 days post -surgery, whichever is later. Serious adverse events that occur more 
than 28 days after surgery and have an attribution of possibly, probably, or definitely related to cetuximab (or other research procedures such as biopsy or 
blood draws) require reporting per table 1.  
 
At each study visit, the investigator will inquire about the occurrence of AE/SAEs since  the last visit. Events  will be followed  for outcome information  until resolution 
or stabilization.  
 
9.3 Characteristics of an Adverse Event  
Any adverse event,  inclusive  of all related study  procedures,  will be examined 
(section 9.1).  
 
9.3.1  Relationship to Study Intervention  
The causality, or attribution, of AEs refers to the relationship of the AE to the 
experimental  intervention (drug/biologic).  The investigator,  using the following  points, 
makes the assessment of whether there is a reasonable possibility of a causal relationship:  
1. Related  (Possible,  Probable,  Definite)  
 
a. The event  is known  to occur  with the study  intervention.  
b. There is a temporal  relationship between  the intervention  and event  onset.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
50 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 c. The event  abates  when  the intervention is discontinued.  
d. The event  reappears  upon a re-challenge with the intervention.  
2. Not Related  (Unlikely,  Not Related)  
 
a. There is no temporal  relationship between  the intervention  and event 
onset.  
b. An alternate etiology  has been established.  
 
Based on the aforementioned points,  the PI assigns attribution of the adverse 
event to the study treatment. Attribution categories are as follows:  
• Definite : The AE is  clearly related to the study treatment  
• Probably : The AE is  likely  related to  the study treatment  
• Possible : The AE may be related to the study treatment  
• Unlikely : The AE is doubtfully  related to the study  treatment  
• Unrelated : The AE is clearly  NOT related  to the study  treatment  
9.3.2  Expectedness of SAEs  
Expected events  are those  that have been previously  identified  as resulting 
from administration of the intervention. An adverse event is considered 
unexpected, for expedited reporting purposes only, when either the type of event or the severity of the event is not listed in:  
• Current  known adverse events  listed  in this protocol  
• Drug  package  insert  (for commercially  available  agent)  
 
 
9.3.3  Severity of Event  
This study will utilize version 5.0 of the CTCAE of the National Cancer Institute for toxicity  and performance reporting.  A copy  of the CTCAE  version 5.0 can be 
downloaded from the NCI website at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTC AE_v5_Quick_Reference_5x7.pdf.  
 
9.4 Reporting Procedures  
Procedures  for Recording Adverse Events  
• AEs will be recorded from time of informed  cons ent until 28 days  post 
discontinuation of study drug or day of surgery, whichever is first.  
• AEs will be recorded regardless  of whether  or not they are considered 
related to the study intervention.  
• AEs will be recorded in the subject’s  medical  record  and in the research 
study records.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
51 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Reporting  Requi rements  for Serious  Adverse  Events  • All AEs considered  related  to study  drug(s)  or procedure will be followed  until 
resolution to ≤ Grade 1 or baseline, deemed clinically insignificant, and/or 
until a new anti -cancer treatment starts, whichever oc curs first.  
• At the 3 month and 12 month follow up visits,  any AEs deemed  by treating 
physician or study PI to be probably related to the research blood draw 
procedure will be recorded at time of visit and followed until resolution to  
≤ Grade  1 or baseline,  deemed  clinically  insignificant.  
 
Procedures  for Recording and Reporting Serious  Adverse Events 
• SAEs  will be reported  from time of informed  consent  until 28 days  after 
discontinuation of cetuximab or definitive surgery, whichever is later.  
• Any SAEs experienced after this 28- day period will only be reported if the 
investigator  suspects  a causal  relationship  (possibly,  probably  or definitely 
related) to the study treatment.  
• SAEs  will be reported  on the SAE Submission  Form  and entered  in SAE tab 
in OnCore within 1 business day of discovery of the event.  
• SAEs  include  events  related and unrelated to the study  drug(s).  
• SAEs  will be recorded  in the subject’s  medical  record  and on the appropriate 
study specific eCRF form within OnCore.  
• All SAEs,  regardless  of relation to study  drug,  will be followed  until resolution 
to ≤ Grade 1 or baseline and/or deemed clinically insignificant and/or until a 
new anti -cancer treatment starts, whichever occurs first.  
• Recurrent  episodes,  complications,  or progression of the initial SAE will be 
reported as follow -up to the original episode within 24 hours of the 
investigator receiving the follow -up information.  
 
Expedited  Reporting of Serious  Adverse Events 
Depending on the nature, severity, and attribution of the serious adverse event an SAE report  will be phoned in, submitted  in writing,  or both according to Table 
1 below. All serious adverse events must also be reported to the UWCCC Data and Safety Monitoring Committee Chair. All serious adverse events must also be reported to the UW IRB (if applicable), and any sponsor/funding agency not already included in the list.  
 
Determine  the reporting  time line for the SAE in question by using the following 
table.  
 
Table  1. Expedited  Reporting Requirements for Adverse Events that Occur  in 
Non-IND/IDE Studies Within 28 Days Post Surgical Intervention, 
 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
52 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
  
NOTE:  Investigators  MUST  immediately  report  to the UWCCC  DSMC,  NIDCR  (via 
Rho)  and the IRB (if applicable)  ANY Serious  Adverse Events, whether  or not they 
are considered related to the investigational agent(s)/intervention. See below.  
An adverse event  is considered  serious  if it results  in ANY of the following  outcomes:  
1) Death.  
2) A life-threatening  adverse  event.  
3) An adverse event  that results  in inpatient  hospitalization  or prolongation of 
existing hospitalization for ≥ 24 hours.  
4) A persistent  or significant  incapacity  or substantial  disruption of the ability  to 
conduct normal life functions.  
5) A congenital  anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life 
threatening, or require hospitalization may be considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may require medical  or surgical intervention to prevent  one of the outcomes  listed  in 
this definition (FDA, ICH E2A and ICH E6).  
ALL SERIOUS adverse events that meet the above criteria* MUST be 
immediately  reported  to the UWCCC within  the timeframes  detailed  in the table  
below:  
Hospitalization  Grade 1 
Timeframes  Grade 2 
Timeframes  Grade 3 
Timeframes  Grade  4 & 5 
Timeframes  
Resulting in 
hospitalization  
≥ 24 hrs  
10 Calendar  Days   
 
24-Hour; 5 
Calendar  Days  Not resulting in 
Hospitalization  
≥ 24 hrs  
Not required 10 Calendar 
Days  
* Hospitalization  for planned  surgical  resection  does  not require  reporting*  
 
Expedited  AE reporting timelines  are defined as: 
• 24-Hour;  5 Calendar  Days – The AE must initially  be reported  within  24 hours 
of learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 24- hour report.  
• 10 Calendar  Days  – A complete expedited report  on the AE must  be 
submitted within 10 calendar days of learning of the AE.  
1 
 
Serious adverse  events  that occur  more than 28 days  after the surgery and  have 
an attribution of possibly, probably, or definitely related to cetuximab (or other research procedures  such  as biopsy  or blood draws)  require reporting  as follows:  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
53 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
  
 
 
SAE Requiring [24] Hour  Reporting Occurs at UWCCC  
Report  to the UWCCC DSMC:  
Reference the SAE SOP (Standard Operating Procedure) and the SAE Reporting 
Workflow for DOTs on the UWCCC website (http://kb.wisc.edu/uwccc)  for specific 
instructions  on how and what  to report  to the UWCCC for [24] hour initial and follow - 
up reports . A follow -up report is required to be submitted within 5 days of the 
initial [24] hour report.  
For this protocol,  the following  UWCCC entities  are required to be notified:  
a. saenotify@uwcarbone.wisc.edu  
b. UWCCC PIs: Justine Yang Bruce, MD and Randall  Kimple,  MD, PhD 
c. UWCCC PM: Diana Trask 
d. Any other  appropriate parties  listed  on the SAE Routing Form  (for follow -up 
reports only)  
 
Report  to the IRB 
Please  refer to the document  “Unanticipated Problems/Adverse Event  Reporting 
Decision Guide” found on the UW Health Science IRB website: 
https://kb.wisc.edu/hsirbs/ . SAEs must be reported to the IRB Chair/director 
within 10 calendar days.  
SAE Requiring [10] Calendar  Day Reporting Occurs at UWCCC 
Report to the UWCCC DSMC:  
Reference the SAE SOP and the SAE Reporting Workflow for DOTs on the 
UWCCC website  (http://kb.wisc.edu/uwccc ) for specific  instructions  on how and 
what to report to the UWCCC for [10] calendar day reports.  
For this protocol,  the following  entities  are required  to be notified:  
a. saenotify@uwcarbone.wisc.edu  
b. UWCCC PIs: Justine Yang Bruce, MD and Randall  Kimple,  MD, PhD 
c. UWCCC PM: Diana Trask 
d. Any other  appropriate parties  listed  on the SAE Routing Form  (for follow -up 
reports only)  
 
Other Reportable Events  
Reporting timeframes  begin when  PI learns  of the occurrence of the event. 
Refer to Table 2.  Expedited  24-hour  notification  followed  by complete  report  within  10 
calendar days for:  
• All Grade  4, and 5 SAEs  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
54 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
  
 
Table  2. Other  Reportable  Events  Timeframe  
Event  Definition  Reporting  
Breach of 
confidentiality  The exposure  of any study  information  or 
communications directly related to a 
study subject to anyone not named as study staff or the release of a study subject’s identifiable information to study staff who were not specified to receive such information in the protocol or IRB  
application.  Within  14 business  days  of 
knowledge of event  
Protocol 
deviation A deviation is an incident involving a 
departure from the IRB -approved 
protocol in the actual conduct of the study. Deviations may result from the action of the participant,  investigator,  or 
staff.  See details  below  
Major 
deviations  Deviations are considered major when 
the unapproved  change(s) in previously 
approved research activities, implemented  without  IRB approval,  may 
potentially adversely affect subjects’ rights, safety, welfare, or willingness to continue participation, or aff ect the 
scientific design of the study and/or the  
integrity  of the resultant  data.  Within  14 business  days  of 
knowledge of event  
Minor 
deviations  Deviations are considered minor when 
the unapproved change(s)  in previously 
approved research activities, implemented without IRB approval, do  
not adversely  affect  subjects or the 
integrity of the study data.  Cumulative minor 
deviations  are reported at 
the time of continuing review.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
55 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
  
Table  2. Other  Reportable  Events  Timeframe  
Event  Definition  Reporting  
Protocol 
violation  An incident involving an intentional 
deviation from the IRB-approved protocol 
that was not implemented in response to 
an emergency situation and that may impact a subject’s rights, safety, and/or welfare,  makes  a substantial  alteration to 
risks to subjects, or affects the scientific design  of the study and/or  the integrity  of 
the resultant data. Violations may also  
be repeated deviations (major or minor) of the same nature. Violations can represent serious or continuing non-  
compliance with the federal regulations and guidelines for ethical conduct of  
human  subject  research.  Within  14 business  days  of 
knowledge of event  
Protocol 
Exceptions  A protocol  exception  is an IRB-approved 
deviation for a single subject or a small group of subjects  but is not a permanent  
revision to the research protocol.  Protocol  exceptions  must 
be approved by local IRB 
prior to implementation.  
 
9.4.1  Unanticipated  Problem  Reporting to IRB and NIDCR  
Incidents or events that meet the OHRP criteria for unanticipated problems require the creation and completion of an unanticipated problem report form. OHRP recommends that investigators include the following information when reporting  an adverse event,  or any other  incident,  experience,  or outcome as an 
unanticipated problem to the IRB:  
 
• appropriate identifying information  for the research  protocol,  such  as the 
title, investigator’s name, and the IRB project number;  
• a detailed  description of the adverse event,  incident,  experience,  or 
outcome;  
• an explanation of the basis for determining that the adverse event, 
incident,  experience,  or outcome represents  an unanticipated problem;  
• a description of any changes  to the protocol  or other  corrective  actions 
that have  been taken  or are proposed in response to the unanticipated 
problem.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
56 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 To satisfy the requirement  for prompt  reporting,  unanticipated problems  will be 
reported using the following timeline:  
 
• Unanticipated  problems  that are serious  adverse  events  will be reported 
to the IRB and to NIDCR within 10 calendar days of the investigator 
becoming aware of the event.  
• Any other unanticipated problem will be reported to the IRB and to NIDCR within  10 calendar  days  of the investigator  becoming aware  of 
the problem.  
• All unanticipated problems  should be reported  to appropriate institutional 
officials  (as required by  an institution’s written  reporting procedures),  the 
supporting agency head (or designee), and OHRP within one month of the IRB’s receipt of the report of the problem from the investigator.  
All unanticipated problems  will be reported  to NIDCR’s  centralized reporti ng 
system via Rho Product Safety:  
• Product  Safety  Fax Line (US):  1-888-746-3293 
• Product  Safety  Fax Line (International): 919- 287-3998  
• Product Safety Email: rho_productsafety@rhoworld.com  
General  questions  about  SAE reporting  can be directed to the Rho Product 
Safety Help Line (available 8:00AM – 5:00PM Eastern Time):  
• US: 1-888-746-7231  
• International:  919-595-6486 
 
9.4.2  Serious  Adverse Event  Reporting to NIDCR 
Any AE meeting the specified Serious Adverse Event criteria  will be  submitted 
on an SAE form to NIDCR’s  centralized safety  system  via Rho Product  Safety. 
This report may be sent by fax or email. Once submitted, Rho Product Safety 
will send a confirmation email to the investigator within 1 business day. The investigator should contact Rho Product Safety if this confirmation is not received. This proc ess applies to both initial and follow -up SAE reports.  
SAE Reporting  Contact  Information:  
 
• Product  Safety  Fax Line (US):  1-888-746-3293 
• Product  Safety  Fax Line (International): 919- 287-3998  
• Product Safety Email: rho_productsafety@rhoworld.com  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
57 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 General  questions  about  SAE reporting can be directed to the Rho Product 
Safety Help Line (available 8:00AM – 5:00PM Eastern Time):  
 
• US: 1-888-746-7231  
• International:  919-595-6486 
The study  clinician  will complete  a Serious  Adverse  Event  Form and submit  via 
fax or email within the following timelines:  
 
• All deaths  and immediately  life-threatening events,  whether  related or 
unrelated, will be recorded on the Serious Adverse Event Form and 
submitted to Product Safety within 24 hours of site awareness.  
• Serious adverse events other than death and immediately life-  
threatening events,  regardless  of relationship,  will be report ed by fax 
within 10 calendar days of site awareness.  
All SAEs  will be followed until resolution  or stabilization.  
 
9.4.3  Reporting of SAEs  and AEs to FDA 
Not applicable.  
 
9.4.4  Events  of Special  Interest  (if applicable)  
Not applicable.  
 
9.4.5  Reporting of Pregnancy  
• Pregnancy  will be reported  from time of first study  drug until 6 months 
after discontinuation of either study drug.  
• Pregnancy will be reported to UW via an unanticipated problem submission  and the NIDCR medical  monitor  within  1 business  day of 
discovery of  the event.  
 
To ensure subject safety, each pregnancy in a subject on study treatment will 
be reported to UW and the NIDCR medical monitor within 1 business day of learning of its occurrence. The pregnancy will be followed to determine outcome, including spontaneous or  voluntary termination, details of the birth, 
and the presence or absence  of any birth defects,  congenital  abnormalities,  or 
maternal and/or newborn complications.  
 
9.5 Halting Rules  
During the conduct of this study, subjects with adverse events and serious 
adverse  events  that are probably  attributed  to cetuximab  will be evaluated and 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
58 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 analyzed weekly  by the principal  investigators.  If >25%  of subjects  have serious 
adverse events that are probably related to pre- operative cetuximab treatment, 
then enrollment for the study will be suspended for further analysis.  
Subsequent review of serious, unexpected, and related AEs will be evaluated 
by the DSMC,  IRB, and the NIDCR.  The NIDCR and local regulatory  authorities 
retain the authority to suspend additional enrollment and administration of cetuximab for the entire study, as applicable.  
 
10 STUDY OVERSIGHT  
A summary  of DSMC  activities  is as follows:  
• Reviews  all clinical trials  conducted at the UWCCC for subject  safety,  protocol 
compliance, and data integrity.  
• Reviews  Adverse Events  recorded by study  team  as described in section  9.4. 
• Reviews all Serious Adverse Events (SAE) requiring expedited reporting, as 
defined in the protocol,  for all clinical trials  conducted  at the UWCCC,  and studies 
conducted at external sites for which the UWCCC acts as an oversight body.  
• Reviews all reports generated through the UWCCC DSMS elements (Internal Audits,  Quality  Assurance  Reviews,  Response Reviews,  Compliance  Reviews, 
and Protocol Summary Reports) described in Section II of this document.  
• Notifies  the protocol  PI of DSMC  decisions  and, if applicabl e, any requirements  for 
corrective action related to data or safety issues.  
• Notifies  the Clinical Research  Committee  (CRC)  of DSMC  decisions  and any 
correspondence from the DSMC to the protocol Principal Investigator.  
• Works  in conjunction with the UW Health  Sciences IRB in the review  of relevant 
safety information as well as protocol deviations, non- compliance, and 
unanticipated problems reported by the UWCCC research staff.  
• Ensures that notification of SAEs requiring expedited reporting is provided to external  sites participating in multi- institutional  clinical trials  coordinated by the 
UWCCC.  
 
Monitoring and Reporting Guidelines  
UWCCC quality assurance and monitoring activities are determined by study 
sponsorship and risk level of the protocol as determined by the PRMC. All protocols (including Intervention Trials, Non- Intervention Trials, Behavioral and Nutritional 
Studies,  and trials conducted under  a Training  Grant)  are evaluated by the PRMC  at the 
time of committee review. UWCCC monitoring requirements for trials without an acceptable external DSMB are as follows:  
 
• Intermediate Monitoring  
Protocols subject to intermediate monitoring generally include UW Institutional Phase  I/II and Phase II Trials. These protocols  undergo review  of subject  safety 
at regularly scheduled DOT meetings where the results of each subject’s  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
59 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 treatment  are discussed  and the discussion  is documented in the DOT  meeting 
minutes. The discussion includes the number of subjects enrolled, significant 
toxicities, dose adjustments, and responses observed. Protocol Summary Reports  are submitted  on a bi-annual  basis  by the study  team  for review  by the 
DSMC.  
 
Review  and Oversight  Requirements  
• Study Progress Review 
o Protocol Summary Reports (PSR) are required to be submitted to the DSMC 
in the timeframe determined by the risk level of the study (quarterly; semi - 
annually;  or annually).  The PSR provides  a cumulative  report  of SAEs,  as well 
as inst ances of noncompliance, protocol deviations, and unanticipated 
problems, toxicities and responses that have occurred on the protocol in the 
timeframe specified. PSRs for those protocols scheduled for review are 
reviewed at each DSMC meeting.  
o Protocol Summary Reports enable DSMC committee members to assess whether significant benefits or risks are occurring that would warrant study 
suspension or closure. This information is evaluated by the DSMC in 
conjunction with other reports of quality assurance activities (e.g., reports  
from Internal Audits, Quality Assurance Reviews, etc.) occurring since the 
prior review  of the protocol  by the DSMC.  Additionally,  the DSMC  requires  the 
study team to submit external DSMB or DSMC reports, external monitoring findings for industry -sponsored studies, and any other pertinent study -related 
information.  
o In the event that there is significant risk warranting study suspension or 
closure, the DSMC will notify the PI of the DSMC findings and ensure the appropriate action is taken for the protocol (e.g., suspension or closure). The 
DSMC  ensures  that the PI reports  any temporary  or permanent  suspension of 
a clinical trial to the appropriate agenci es. DSMC findings and requirements 
for follow -up action are submitted to the CRC.  
 
 
11 CLINICAL  SITE  MONITORING 
Clinical site monitoring is conducted to ensure that the rights of human subjects are 
protected, that the study is implemented in accordance with t he protocol and/or other 
operating procedures,  and that the quality  and integrity  of study  data and data collection 
methods  are maintained.  Monitoring  for this study  will be performed  by NIDCR’s  Clinical 
Research Operations and Management Support (CROMS) contractor. The monitor will evaluate study processes and documentation based on NIDCR standards and the International  Conference  on Harmonisation  (ICH),  E6: Good Clinical Practice  guidelines 
(GCP ). 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
60 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Details  of clinical site monitoring  will be documented in a Clinical Monitoring  Plan (CMP) 
developed by the CROMS contractor, in collaboration with the NIDCR Office of Clinical 
Trials and Operations Management (OCTOM) and the NIDCR Program  Official. The 
CMP  will specify the frequency  of monitoring,  monitoring procedures,  the level of clinical 
site monitoring activities (e.g., the percentage of subject data to be reviewed), and the distribution of monitoring reports. Some monitoring activiti es may be performed 
remotely, while others will take place at the study site(s). Staff from the CROMS contractor will conduct monitoring activities and provide reports of the findings and associated action items in accordance with the details described in the CMP. Documentation of monitoring activities and findings will be provided to the site study team,  the study  PIs, OCTOM,  and the NIDCR.  The NIDCR reserves  the right to conduct 
independent audits as necessary.  
 
12 STATISTICAL CONSIDERATIONS  
 
12.1 Study Hypotheses 
The primary objective of this window of opportunity trial is to test the hypotheses that elevated AXL and HER3 can predict cetuximab resistance (CTXR)  in head and neck  cancer  patients.  Following  informed  consent,  tumor 
tissue from the pre- treatm ent/research biopsy will be obtained for further 
analysis. The participant will then receive two weekly doses of cetuximab during the interval between research biopsy and surgery, ensuring that no delay in standard of care (SOC) will occur. At the time of surgery, additional tumor tissue will be obtained for study analysis.  
 
Correlative studies will include the measurement of AXL and HER3 expression from the pre-treatment/research biopsy  as well as collection  of circulating  tumor 
cells. Tissue from the pre- treatment/research biopsy will be utilized for patient - 
derived xenograft (PDX) development.  
 
12.2 Sample Size Considerations  
We plan to enroll 36 HNSCC patients, powered on the basis of the primary study endpoint:  the clinical response rate to cetuximab according to RECIST 
criteria in low AXL vs. high AXL patients (measured using VECTRA/inForm software).  Previous  data show  that 1 in 3 patients  respond  to cetuximab,  and 
about one- third (21/57 or 37%) of HNSCC patients have high AXL 
expression.
37 This sample  size is based  on 90% power  to detect  a difference 
between a response rate of 20% in the high AXL (2+ or 3+) group  vs. 65% in 
the low AXL (0 or 1) group, with an expected ratio of 2:1 low vs. high AXL expression participants. One- sided type I error was fixed at 5%.  
 
For evaluation of safety endpoints, any participant that undergoes a research 
biopsy  will be included.  For evaluation of efficacy,  molecular/correlative studies, 
and creation of PDXs, participants must receive both cetuximab doses in their  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
61 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 entirety  and have  surgical  resection  of the tumor.  If a participant  is unevaluable 
for these endpoints, then the patient will be replaced at the discretion of the 
principal investigator.  
 
 
12.3 Planned Interim  Analyses (if applicable)  
Not applicable.  
 
12.4 Final Analysis Plan  
Analysis of Primary  Endpoints  
The relationship between  AXL expression  as a continuous  variable with clinical 
response will be analyzed using the Wilcoxon rank sum test.  
 
Analysis of Secondary  Endpoints  
The safety of pre- operative cetuximab, as evaluated by hospital re- admissions 
for wound  care or surgical  complications  attributed  to cetuximab  within  28 days 
after surgery, will be reported as a proportion including an exact 95% confidence interval.  
 
Analy sis of Correlative  Endpoints  
Summary statistics of the change in Ki67 (ΔKi67), as established by the surgical  specimen,  will be reported  for the response to cetuximab endpoint. 
Correlation between ΔKi67 and putative biomarkers will be analyzed as a continuous variable and will be tested using Pearson’s correlation coefficient. Correlation between two biomarkers such as AXL and HER3 expression as continuous variables wil l be investigated using Pearson’s 
correlation coefficient.  
 
Summary statistics will be used to report circulating tumor cells at each time 
point and the changes between time points. The association of change in 
circulating  tumor  cells with ΔKi67  (early  response)  will be explored graphically 
and with Pearson’s correlation coefficient.  
 
 
13 SOURCE  DOCUMENTS  AND ACCESS  TO SOURCE  DATA/DOCUMENTS  
Study staff will maintain appropriate medical and research records for this study, in compliance with ICH E6, Section 4.9  and regulatory and institutional requirements for 
the protection of confidentiality of subjects. Study staff will permit authorized representatives of NIDCR and regulatory agencies to examine (and when required by applicable law, to copy)  research  records  for the purposes  of quality  assurance reviews, 
audits, and evaluation of the study safety, progress and data validity.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
62 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 Source documents will include all records within the HealthLink Electronic Medical 
Records system such as hospital records , clinical and office charts, laboratory notes, 
memoranda, pharmacy dispensing records, copies or transcriptions certified after verification as being accurate and complete, photographs or digital photo files, x -rays, 
and subject files and records kept at the pharmacy, at the laboratories, and medico-  
technical  departments  involved in the clinical trial. In addition,  protocol  specific  forms  will 
be designed which require treating physician signature to serve as source documents.  
This may include  forms  such  as toxicity  forms  with grading and attribution and tumor 
measurement forms.  
 
14 QUALITY  CONTROL  AND QUALITY  ASSURANCE  
 
14.1 Monitoring,  Auditing,  and Data  Quality  Control  and Assurance Measures 
by Study Team.  
All personnel involved in FDA regulated clinical trial activities are required to complete the Human Subjects Training and Good Clinical Practice (GCP) via CITI every 3 years. Trainin g is monitored  at each IRB continuing review  and with the submission  of protocol 
amendments.  
 
At the protocol level, the Principal Investigators will assign and document protocol responsibilities based on study roles.  Training on all IRB approved protocols (initial 
version and subsequent amendments) are documented for each person listed as key personnel on the University of Wisconsin Health Sciences IRB application. These 
documents  are retained with the study  regulatory  files, and collection  is coordinated  by 
Human Oncology regulatory staff.  
 
Eligibility  checklists are signed  by the study  coordinator  and the treating physician  prior 
to enrollment. Adverse event grading and attributions are assigned by physicians at clinic visits and will be signed by the physician at that time.  
 
A data report will be run quarterly to ensure study data is entered into the study 
database in a timely  manner.  After  the report  is run, the Research Program  Manager 
will review and audit at least 25% of accrued cases since the last report was run.  
Auditing assistance will be provided by a study coordinator not involved in the cases being audited.  Audits  will include case  review  (Informed  consent,  eligibility,  response, 
toxicity) and source document review.  
 
Other  relevant  UWCCC SOPs  that would  be followed  include:  
 
• Adverse  Event Assessment  and Documentation_SOP  
• CTRP  and ClinicalTrials.gov  Reporting_SOP  
• Delegation of Authority  Log_SOP  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
63 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 • DSMS  Reporting Guidelines_SOP  
• Informed Consent  Process_SOP  
• Maintaining a Regulatory  File_SOP  
• OnCore Data  Quality  Assurance_SOP  
• Protocol Deviation_Guidance  
• Reportable Events_SOP  
• Reporting  of Serious  Adverse  Events  (SAEs)  at UWCCC,  1SP,  JC, 
And Affiliate Sites_SO P 
• Source Documentation_SOP  
• Study  Close  Out_SOP  
 
15 ETHICS/PROTECTION  OF HUMAN SUBJECTS  
 
15.1 Ethical Standard  
The investigator will ensure that this study is conducted in full conformity with 
the principles  set forth in The Belmont  Report:  Ethical  Principles  and Guidelines 
for the Protection of Human Subjects of Research, as drafted by the US National Commission f or the Protection of Human Subjects of Biomedical and 
Behavioral  Research  (April  18, 1979)  and codified  in 45 CFR Part 46 and/or  the 
ICH E6.  
15.2 Institutional Review Board  
The protocol, informed consent form(s), recruitment materials, and all subject 
materials  will be submitted  to the IRB for review  and approval.  Approval  of both 
the protocol and the consent form must be obtained before any subject is enrolled. Any amendment to the protocol will require review and approval by the IRB before the changes are implemented in the study.  
 
15.3 Informed Consent Process  
Informed  consent  is a process  that is initiated  prior to the individual  agreeing to 
participate in the study  and continues  throughout  study  participation.  Extensive 
discussion of risks and possible benefits of study participation will be provided to subjects and their famili es, if applicable. A consent form describing in detail 
the study procedures and risks will be given to the subject. Persons who are not fluent in English and persons with impaired decision- making capacities will 
not be eligible for enrollment in this study . 
 
Consent forms will be IRB -approved, and the subject is required to read and 
review  the document  or have the document  read to him or her. The investigator  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
64 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 or designee will explain the research study to the subject and answer any 
questions that may arise. The subject will sign the informed consent document prior to any study -related assessments or procedures. Subjects will be given 
the opportunity to discuss the study with their surrogates or think about it prior 
to agreeing to participate. They may withdraw consent at any time throughout the course of the study. A copy of the signed informed consent document will be given  to subjects  for their records.  The rights and welfare  of the subjects  will 
be protected by emphasizing to them that the quality of their clinical care will not be adversely affected if they decline to participate in this study.  
 
 
The consent  process  will be documented in the clinical or research  record.  
 
15.4 Exclusion of Women, Minorities, and Children (Special Populations)  
Children  are excluded from this study  because insufficient  data are available in 
adults to judge potential risks in children.  
Individuals  of any gender  or racial/ethnic  group  may participate  in this study.  
 
15.5 Subject Confidentiality  
Subject confidentiality is strictly held in trust by the investigators, study staff, 
and the sponsor(s)  and their agents.  This confidentiality  is extended to cover 
testing of biological samples and genetic tests in addition to any study information relating to subjects.  
 
All members of the study team will be listed on the IRB application and are required to undergo annual HIPAA training to ensure responsible conduct regarding protec ted health information (PHI) in research. In addition, Human 
Subjects  Training and Good Clinical Practice  trainings  are required every  three 
years for members of the study team.  
 
The study protocol, documentation, data, and all other information generated will be held in strict  confidence.  No information  concerning the study  or the data 
will be released to any unauthorized third party without prior written approval of the sponsor.  All PHI is stored securely on password protected servers.  
 
The study monitor or other authorized representatives of the sponsor may inspect all study docum ents and records required to be maintained by the 
investigator, including but not limited to, medical records (office, clinic, or hospital)  for the study  subjects.  The clinical study  site will permit  access to such 
records.  
 
To further protect the privacy of study participants, the Secretary, Health and 
Human  Services (HHS),  has issued  a Certificate  of Confidentiality  (CoC)  to all 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
65 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 researchers  engaged in biomedical,  behavioral,  clinical,  or other  human 
subjects research funded wholly or in part by the federal government.  
Recipients of NIH funding for human subjects research are required to protect 
identifiable  research  information  from forced disclosure  per the terms  of the NIH 
Policy (https://huma nsubjects.nih.gov/coc/index). As set forth in 45 CFR Part 
75.303(a) and NIHGPS Chapter 8.3, recipients conducting NIH -supported 
research covered by this Policy are required to establish and maintain effective internal controls (e.g., policies and procedure s) that provide reasonable 
assurance that the award is managed in compliance with Federal statutes, regulations, and the terms and conditions of award. It is the NIH policy that investigators and others who have access to research records will not disclose identifying information except when the participant consents or in certain instances when federal, state, or local law or regulation requires disclosure.  
NIH expects  investigators  to inform  research participants  of the protections  and 
the limits to protec tions provided by a Certificate issued by this Policy.  
15.6 Future  Use of Stored  Specimens and  Other Identifiable  Data  
Residual samples will be relinquished to the TSB Biobank (2016- 0934) for 
future  exploratory  analyses  at the termination of this study.  All subjects will 
have  already  signed a consent for the TSB Biobank protocol  as part of the 
inclusion criteria.  
Any use of specimens  outside the context  of this protocol,  including  genetic 
testing, will only occur after IRB approval.  
 
 
 
16 DATA HANDLING  AND RECORD  KEEPING  
This study  will report  clinical data using  the UWCCC data management  system  utilizing 
study specific case report forms. Key study personnel are trained on the use of case 
report forms and will comply with protocol specific instructions for data collection.  
 
Patient  demographics,  patient  specific  study  treatment  calendars,  adverse  events  and 
other information will be maintained with the UWCCC data management system.  
 
Participant data will be collected using protocol specific case report forms (CRFs). The CRFs will be approved by the study’s Principal Investigator and the study biostatistician prior to release for use. The Study Coordinator or designee will be responsible for registering  the patient  into the UWCCC data management  system  at time of study  entry, 
completing CRFs based on the patient specific calendar, and updating the patient record until patient death or end of required study participation.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
66 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 16.1 Data  Management  Responsibilities  
Data  collection  and accurate documentation  are the responsibility  of the study 
staff under the supervision of the inv estigator. All source documents and 
laboratory reports must be reviewed by the study team and data entry staff, 
who will ensure that they are accurate and complete. Unanticipated problems and adverse events must be reviewed by the investigator or designee.  
 
UWCCC Radiotherapy  will serve  as the Clinical Research Office  for this trial. 
 
16.2 Data  Capture  Methods  
Data will be collected through the web- based clinical research platform,  
OnCore (Forte Research),  a system compliant with  Good Clinical Practices and 
Federal  Rules  and Regulations.  UWCCC personnel  will coordinate and manage 
data for quality control assurance and integrity. All data will be collected and entered into OnCore by study site personnel.  
 
16.3 Types of Data  
Patient  demographics,  patie nt medical  history,  patient  specific  study  treatment 
calendars, adverse events, laboratory/pathology reports obtained during the course of treatment and afterwards, e.g., blood tests, biopsy results), findings from physical exams, and imaging scan reports/outcomes will be maintained with the UWCCC data management system.  
 
 
16.4 Schedule and Content of Reports  
The UWCCC Protocol Review and Monitoring Committee (PRMC) determines 
the level of risk, thus the appropriate timelines for review of study documents, conduct  and accrual.  Protocol  Safety  Reports  are run, reviewed  and signed off 
by the study PI per the determined schedule. PSRs are then sent for review to the Data Safety Monitoring Committee (DSMC).  A summary of the DSMC 
decisions for this study will be provided to the medical monitor at NIDCR according to the determined DSMC meeting schedule.  
 
Protocol Safety Reports include information such as accrual, adverse events, serious  adverse events,  and unanticipated problems.  Annual  review  by the UW 
Health  Sciences IRB will review  accrual,  reportable  events,  and study  progress. 
A copy of the continuing review and supporting documents will be submitted to NIDCR at time of submission to the IRB.  
 
16.5 Study  Records  Retention  
Shadow  research charts  with original  consent  forms  and documents  specifically 
created for this study will be maintained in the Department of Human Oncology  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
67 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 until the study is terminated.  The records will then be sent to Wisconsin State 
Records Archiving facility for long term storage (10 years) and re- archived as 
needed.  Study  records  will be maintained for at least  three  years  from the date 
that the grant federal financial report (FFR) is submitted to the NIH.  
 
16.6 Protocol Deviations 
Except in the case  of a medical  emergency,  no protocol  deviation  is authorized. 
Changes to the protocol will be established by amendments by the Principal 
Investigator approved by the UW HS IRB. Protocol deviations may affect the conduct  of the study  from legal  and ethical  points  of view and may influence the 
statistical analysis and pertinence of the study. Medical emergencies have to  
be handled in the patients’ best interest. The investigator has to contact the Sponsor to clarify if a patient may continue in the study when a protocol violation out of medi cal reasons has occurred. Protocol deviations that are not 
identifiable from the eCRF have to be recorded in a protocol deviation form.  
Protocol  deviations  will be evaluated at the data review  meeting before 
database lock and will be described in the statistical analysis plan.  
 
It is the responsibility  of the Principal  Investigator  to use continuous  vigilance  to 
identify and report deviations within 7 working days of identification of the protocol deviation, or within 7 working days of the scheduled protocol- required 
activity. All deviations must be addressed in study source documents and reported to NIDCR and to the UW HS IRB per their policies. The Principal Investigator is responsible for knowing and adhering to the reviewing IRB requirements.  
 
 
 
17 PUBLICATION/DATA  SHARING POLICY  
This study  will comply  with the NIH Public  Access Policy , which  ensures  that the public 
has access to the published results of NIH funded research. It requires scientists to 
submit final peer -reviewed journal manuscripts that arise from NIH funds to the digital 
archive PubMed Central  upon acceptance for publication.  
 
The clinical trial will be registered  on ClinicalTrials.gov , which  is sponsored  by the 
National Library of Medicine.  
 
The study  investigators  will have sole right to determine  the content  of the presented 
and published data.  As PIs, Drs. Bruce  and Kimple  will retain  a spot as both first and 
last author  on all manuscripts, unless either  elects  to forgo this. Co- Is will have input 
into all remaining authorship spots.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
68 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
  
 
18 LITERATURE REFERENCES  
 
1. Erbitux(R) [package insert]  IL, Branchburg,  NJ; October  2016.  (Accessed  May 
15, 2017, at http://uspl.lilly.com/erbitux/erbitux.html .). 
2. Jemal  A, Bray F, Center  MM, Ferlay  J, Ward  E, Forman  D. Global  cancer 
statistics. CA: a cancer journal for clinicians 2011;61:69- 90. 
3. Siegel  RL, Miller  KD, Jemal  A. Cancer  Statistics,  2017.  CA: a cancer  journal  for 
clinicians 2017;67:7- 30. 
4. Siegel  RL, Miller  KD, Jemal  A. Cancer  statistics,  2015.  CA: a cancer  journal  for 
clinicians 2015;65:5- 29. 
5. Laramore GE, Scott  CB, al-Sarraf  M, et al. Adjuvant  chemotherapy  for resectable 
squamous cell carcinomas of the head and neck: report on Intergroup Study 
0034. International journal of radiation oncology, biology, physi cs 1992;23:705 - 
13. 
6. Cancer  Genome Atlas  N. Comprehensive genomic  characterization of head and 
neck squamous cell carcinomas. Nature 2015;517:576- 82. 
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and nec k cancer: 5- year survival data from a 
phase 3 randomised trial, and relation  between  cetuximab- induced rash and 
survival. Lancet Oncol 2010;11:21- 8. 
8. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous -cell carcinoma  of the head and neck.  The New England journal  of 
medicine 2006;354:567- 78. 
9. Vermorken JB, Mesia  R, Rivera  F, et al. Platinum -based chemotherapy  plus 
cetuximab in head and neck cancer. The New England journal of medicine 2008;359:1116- 27. 
10. Vermorken JB, Trigo  J, Hitt R, et al. Open- label,  uncontrolled,  multicenter  phase 
II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinu m-based therapy. J Clin Oncol 
2007;25:2171- 7. 
11. Gilbert  J, Schell  MJ, Zhao X, et al. A randomized phase  II efficacy and correlative 
studies  of cetuximab  with or without  sorafenib  in recurrent  and/or  metastatic  head 
and neck squamous cell carcinoma. Oral Oncol 2015;51:376- 82. 
12. Brand TM, Iida M, Wheeler  DL. Molecular  mechanisms  of resistance  to the 
EGFR monoclonal antibody cetuximab. Cancer Biol Ther 2011;11:777- 92. 
13. Bauman JE, Duvvuri U, Gooding WE, et al. Randomiz ed, placebo- controlled 
window  trial of EGFR,  Src, or combined  blockade in head  and neck  cancer.  JCI 
insight 2017;2:e90449.  
14. Schmitz S, Hamoir M, Reychler H, et al. Tumour response and safety of 
cetuximab in a window  pre-operative study  in patients  with squamous  cell 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
69 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 carcinoma of the head  and neck.  Annals  of oncology  : official journal  of the 
European Society for Medical Oncology 2013;24:2261- 6. 
15. Viloria -Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor 
effect of epider mal growth  factor  receptor -blocking  antibodies  in vivo: a role for 
altered tumor angiogenesis. Cancer research 2001;61:5090- 101. 
16. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular 
endothelial  growth  factor  receptor  tyrosine  kinase  inhibitor,  in human  cancer  cells 
with acquired resistance to antiepidermal growth factor receptor therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10:784 -93. 
17. Bianco  R, Rosa  R, Damiano  V, et al. Vascular  endothelial  growth factor  receptor - 
1 contributes to resistance to anti -epidermal growth factor receptor drugs in 
human cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14:5069 -80. 
18. Wheeler  DL, Huang  S, Kruser  TJ, et al. Mechanisms  of acquired resistance  to 
cetuximab: role of HER (ErbB) family members. Oncogene 2008;27:3944- 56. 
19. Hatakeyama H, Cheng  H, Wirth  P, et al. Regulation  of heparin- binding EGF-like 
growth factor by miR -212 and acquired cetuximab- resistance in head and neck 
squamous cell carcinoma. PloS one 2010;5:e12702.  
20. Li C, Iida M, Dunn EF, Ghia  AJ, Wheeler  DL. Nuclear  EGFR  contributes  to 
acquired resistance to cetuximab. Oncogene 2009;28:3801- 13. 
21. Lu Y, Li X, Liang K, et al. Epidermal  growth factor  receptor  (EGFR)  ubiquitination 
as a mechanism of acquired resistance escaping treatment by the anti -EGFR 
monoclonal antibody cetuximab. Cancer research 2007;67:8240- 7. 
22. Fuchs  BC, Fujii T, Dorfman  JD, et al. Epithelial- to-mesenchymal  transition  and 
integrin- linked kinase mediate sensitivity to epidermal growth factor receptor 
inhibition in human hepatoma cells. Cancer research 2008;68:2391 -9. 
23. Kim SM, Kim JS, Kim JH, et al. Acquired  resistance  to cetuximab  is mediated by 
increased PTEN instability and leads cross -resistance to gefitinib in HCC827 
NSCLC cells. Cancer Lett 2010;296:150- 9. 
24. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3  (ErbB3)  expression and activity  attenuates  antitumor  effect 
of PI3K inhibitors. Proc Natl Acad Sci U S A 2012;109:2718- 23. 
25. Engelman JA, Zejnullahu K, Mitsudomi  T, et al. MET  amplification  leads  to 
gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039- 43. 
26. Garrett  JT, Olivares  MG, Rinehart  C, et al. Transcriptional  and posttranslational 
up-regulation of HER3  (ErbB3) compensates  for inhib ition of the HER2  tyrosine 
kinase. Proc Natl Acad Sci U S A 2011;108:5021- 6. 
27. Montero- Conde C, Ruiz-Llorente S, Dominguez  JM, et al. Relief  of feedback 
inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF -mutant thyroid carcinomas. Cancer Discov 
2013;3:520- 33. 
28. Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM -121, is active in 
cancers  with ligand -dependent  activation.  Cancer  research 2010;70:2485- 94. 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
70 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 29. Sergina  NV, Rausch M, Wang  D, et al. Escape  from HER- family  tyrosine  kinase 
inhibitor therapy by the kinase- inactive HER3. Nature 2007;445:437- 41. 
30. Yarden Y, Sliwkowski MX. Untangli ng the ErbB  signalling  network.  Nat Rev Mol 
Cell Biol 2001;2:127- 37. 
31. Fruman DA, Rommel  C. PI3K  and cancer:  lessons,  challenges  and opportunities. 
Nat Rev Drug Discov 2014;13:140- 56. 
32. Zoncu R, Efeyan  A, Sabatini  DM. mTOR:  from growth signal  integration to 
cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21- 35. 
33. Benavente S, Huang  S, Armstrong  EA, et al. Establishment  and characterization 
of a model of acquired resistance to epidermal growth factor receptor targeting 
agents in human c ancer cells. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2009;15:1585- 92. 
34. Wheeler DL, Iida M, Kruser TJ, et al. Epidermal growth factor receptor cooperates  with Src family  kinases  in acquired resistance  to cetuximab.  Cancer 
Biol Ther 2009;8:696- 703. 
35. Brand  TM, Iida M, Stein  AP, et al. AXL mediates  resistance  to cetuximab 
therapy. Cancer research 2014;74:5152- 64. 
36. Iida M, Brand  TM, Starr  MM, et al. Overcoming  acquired resistance  to cetuximab 
by dual targeting  HER family  receptors  with antibody -based therapy.  Mol Cancer 
2014;13:242.  
37. Brand TM, Iida M, Stein  AP, et al. AXL Is a Logical  Molecular  Target  in Head and 
Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2015;21:2601- 12. 
38. Swick AD, Prabakaran PJ, Miller MC, et al. Cotargeting mTORC and EGFR Signaling  as a Therapeutic  Strategy  in HNSCC.  Molecular  cancer  therapeutics 
2017;16:1257- 68. 
39. Iida M, Brand  TM, Starr  MM, et al. Sym004,  a novel  EGFR  antibody  mixture,  can 
overcome acquired resistance to cetuximab. Neoplasia 2013;15:1196- 206. 
40. Gross ND, Bauman JE, Gooding WE, et al. Erlotinib, erl otinib -sulindac versus 
placebo:  a randomized,  double- blind,  placebo -controlled window trial in operable 
head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2014;20:3289- 98. 
41. Klintman  M, Dowset t M. Early  Surrogate Markers  of Treatment  Activity:  Where 
Are We Now? J Natl Cancer Inst Monogr 2015;2015:24- 8. 
42. Berruti  A, Generali  D, Bertaglia  V, et al. Intermediate  endpoints  of primary 
systemic therapy in breast cancer patients. J Natl Cancer Inst Monogr 2011;2011:142- 6. 
43. Dowsett  M, Smith  I, Robertson J, et al. Endocrine therapy,  new biologicals,  and 
new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr 2011;2011:120- 3. 
44. Bjarnadottir  O, Romero  Q, Bendahl  PO, et al. Targeting  HMG -CoA reductase 
with statins  in a window -of-opportunity  breast  cancer  trial. Breast  Cancer  Res 
Treat 2013;138:499- 508. 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
71 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 45. Foroni C, Milan M, Strina C, et al. Pure anti -tumor effect of zoledronic acid in 
naive bone- only metastatic  and locally  advanced breast  cancer:  proof  from the 
"biological window therapy". Breast Cancer Res Treat 2014;144:113 -21. 
46. Hadad SM, Coates P, Jordan LB, et al. Evidence for biological effects of 
metformin in operable breast cancer: biomarker analysis in a pre- operative 
window  of opportunity  randomized trial. Breast  Cancer  Res Treat  2015;150:149-  
55. 
47. Joshua AM, Zannella VE, Downes MR, et al. A pilot 'wi ndow of opportunity' 
neoadjuvant  study  of metformin in localised  prostate cancer.  Prostate Cancer 
Prostatic Dis 2014;17:252- 8. 
48. Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast cancer: a prospective window of opportunity  neoadjuvant  study.  Breast  Cancer  Res Treat 
2012;135:821- 30. 
49. Romero Q, Bendahl PO, Klintman M, et al. Ki67 proliferation in core biopsies versus surgical  samples  - a model  for neo-adjuvant  breast  cancer  studies.  BMC 
Cancer 2011;11:341.  
50. Hadad S, Iwamoto  T, Jordan  L, et al. Evidence for biological  effects  of metformin 
in operable breast cancer: a pre- operative, window -of-opportunity, randomized 
trial. Breast Cancer Res Treat 2011;128:783- 94. 
51. Plaks  V, Koopman  CD, Werb  Z. Cancer.  Circulating  tumor  cells.  Science 
2013;341:1186- 8. 
52. Lin H, Balic M, Zheng S, Datar R, Cote RJ. Disseminated and circulating tumor cells:  Role in effective  cancer  management.  Crit Rev Oncol  Hematol  2011;77:1-  
11. 
53. Grisanti S, Almici C, Consoli F, et al. Circulating tumor cells in patients with 
recurrent  or metastatic  head and neck  carcinoma:  prognostic  and predictive 
significance. PloS one 2014;9:e103918.  
54. Myung JH, Launiere CA, Eddington DT, Hong  S. Enhanced tumor  cell isolation 
by a biomimetic  combination of E-selectin  and anti-EpCAM:  implications  for the 
effective separation of circulating tumor cells (CTCs). Langmuir 2010;26:8589-  
96. 
55. Myung JH, Gajjar KA, Saric J, Eddington DT, Hong S. Dendrimer -mediated 
multivale nt binding for the enhanced capture  of tumor  cells.  Angew  Chem  Int Ed 
Engl 2011;50:11769- 72. 
56. Myung JH, Gajjar KA, Chen J, Molokie RE, Hong S. Differential detection of tumor  cells using a combination of cell rolling,  multivalent  binding,  and multiple 
antibodies. Anal Chem 2014;86:6088- 94. 
57. Myung JH, Eblan MJ, Caster JM, et al. Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.  Clinical cancer  research : an official journal  of the American  Association 
for Cancer Research 2018;24:2539- 47. 
58. Bozec A, Ilie M, Dassonville O, et al. Significance of circulating tumor cell detection using the CellSearch system in patients with locally advanced head and neck  squamous  cell carcinoma.  Eur Arch Otorhinolaryngol  2013;270:2745- 9. 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
72 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 59. Grobe A, Blessmann M, Hanken H, et al. Prognostic relevance of circulating 
tumor  cells in blood and disseminated tumor  cells in bone marrow  of patients  with 
squamous cell carcinoma of the oral cavity. Clinical cancer research : an official journal of the American Association for Cancer Research 2014;20:425- 33. 
60. Nichols  AC, Lowes  LE, Szeto  CC, et al. Detection of circulating tumor  cells in 
advanced head and neck cancer using the CellSearch system. Head & neck 2012;34:1440- 4. 
61. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent  and/or  metastatic  squamous  cell carcinoma of 
the head and neck in patients who previously failed platinum -based therapies. 
Cancer 2008;112:2710 -9. 
62. Jonker  DJ, O'Callaghan  CJ, Karapetis  CS, et al. Cetuximab for the treatment  of 
colorectal cancer. The New England journal of medicine 2007;357:2040- 8. 
63. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory  metastatic  colorectal  cancer. 
The New England journal of medici ne 2004;351:337- 45. 
64. Lacouture ME, Anadkat  MJ, Bensadoun RJ, et al. Clinical practice  guidelines  for 
the prevention and treatment of EGFR inhibitor -associated dermatologic 
toxicities. Support Care Cancer 2011;19:1079- 95. 
65. Eisenhauer  EA, Therasse  P, Bogaerts  J, et al. New response evaluation criteria 
in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228- 47. 
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
73 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 APPENDICES  
A: SCHEDULE  OF EVENTS  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
74 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 APPENDIX  A: SCHEDULE  OF EVENTS  
When calculating days of tests and measurements, the day a test or measurement is done is 
considered  Day 0. Therefore,  if a test were done on a Monday, the Monday one week  later would 
be considered Day 7. 
 
 
Study  Visit  1 
and 2 Study  
Visit  3 Study  
Visit  4 Study  
Visit  5  
SOC  SOC  
Follow  up 1 SOC  
Follow  up 
2 SOC  
Follow  up 3 
  
 
Screening/ 
Baseline1  
 
Dose 
1  
 
Dose  
22,  
 
Safety 
Eval11  
 
 
Surgery   
1 mo post- 
op +/- 2 
wk 3 mo 
post- 
definitiv 
e care10 
+/- 4 wk 12 mo 
post- 
definitive 
care10 
+/- 4 wk 
 REQUIRED  ASSESSMENTS  
Informed  consent  X3        
Demographics  X        
Medical  History  X        
Concurrent  meds 
review  X   X     
Physical  exam  X   X  X X X 
Vitals  signs  X X X13 X  X X X 
Height  X        
Weight  X X4  X  X X X 
ECOG  
Performance  status  X   X  X X X 
CBC  with diff X X4  X     
Serum  chemistry,5 X X4 X9 X     
Pregnancy  test for 
WOCP   X6       
Adverse  event 
evaluation7 X X X X     
 DISEASE  ASSESSMENT  
Tumor 
measurements by 
clinical  assessment  X   
X     
Neck  Imaging12       X X 
 TREATMENT  
Cetuximab   X X      
 CORRELATIVE  STUDIES  
Tumor  tissue  from 
surgery      X    
Blood  collection 
for circulating  
tumor  cells X    
X8 X X X 
Research biopsy 
for biologic 
correlative  studies  X        
FOOTNOTES  
1. Pre-study tests to be done  within  21 days of dose 1 cetuximab  therapy.  
A Window  of Opportunity Trial  of Cetuximab  in Patients  with HNSCC 
Protocol UW18098  6/26/2020  
75 Based  on NIDCR  Clinical  Trial (Interventional)  Protocol  Template  v4.0 - 20140103   
 2. Time  between  doses:  7 days (+/-3 days)  
3. Informed  consent  to be obtained  within  28 days of starting  treatment.  
4. If screening/baseline procedures  are within  7 days prior  to cetuximab  dose 1, they don’t  need  to be repeated  on day of dose 1. 
5. Serum  chemistry  should include:  sodium,  potassium,  chloride,  bicarbonate,  BUN,  creatinine,  glucose,  AST,  ALT,  alkaline 
phosphatase, total bilirubin, calcium, magnesium, protein, albumin.  
6. A negative  serum/urine  pregnancy test is required  within  7 days prior  to cetuximab  dose 1. 
7. For subjects  with unresolved treatment -related  toxicity,  follow  as medically  appropriate  until resolution  or stabilization.  
8. Pre-surgical  blood draw  for circulating  tumor  cells in serum  should be done  within  1 day prior  to surgery.  
9. Prior  to dose 2, required  labs:  magnesium,  calcium  and potassium  
10. Definitive  therapy  is defined  as surgery  alone,  surgery + XRT  or Surgery  + chemoXRT  
11. Within  7 days prior  to surgery,  but as close  as possible  to surgery.  
12. May include  any of the SOC  imaging  such as PET/CT,  PET/MRI,  CT or MRI 
13. Blood Pressure  only 